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Summary 
Chronic kidney disease (CKD) is a public health problem that increases the risk of 
cardiovascular morbidity and mortality worldwide. Uremic cardiomyopathy is the clinical 
phenotype of cardiac diseases that accompanies CKD and is most commonly manifested as 
left ventricular hypertrophy (LVH) with fibrosis and diastolic dysfunction (DD). Angiotensin-
II plays a major role in the development of uremic cardiomyopathy via angiotensin-II receptor 
type 1 (AT1) receptors that could induce nitro-oxidative stress and inflammatory mechanisms. 
However, the precise molecular mechanisms in the development of uremic cardiomyopathy 
are still unknown. Indeed, the exact role of beta-3 adrenergic receptors (β3-AR) in the 
development of uremic cardiomyopathy is uncharacterized yet. In hypertension-induced heart 
failure, the β3-AR is up-regulated and coupled to endothelial nitric oxide synthase (eNOS)-
mediated pathways exerting antiremodeling effects. Thus, our present study aimed to compare 
the effects of angiotensin-II receptor blocker (ARB) losartan and β3-AR agonist mirabegron 
on uremic cardiomyopathy in a rat model. Therefore, CKD was induced by 5/6th nephrectomy 
in male Wistar rats. Sham-operated rats served as controls. Five weeks after the operations, 
rats were randomized into four groups: 1) sham-operated, 2) CKD, 3) losartan-treated (10 
mg/kg/day) CKD, and 4) mirabegron-treated (10 mg/kg/day) CKD groups. 13 weeks after the 
operations, serum carbamide and creatinine concentrations, and urine protein levels were 
increased, meanwhile creatinine clearance was reduced in the 5/6-nephrectomized rats 
proving the development of CKD. In our present study, losartan failed to improve the 
aforementioned laboratory parameters of CKD. In our CKD model, mirabegron worsened the 
proteinuria and renal anemia, and also increased serum total cholesterol and LDL-cholesterol 
levels. At week 13, echocardiographic signs of LVH and DD developed, proving the presence 
of uremic cardiomyopathy in the 5/6-nephrectomized rats at the endpoint of the experiments. 
Indeed, histology revealed cardiomyocyte hypertrophy and interstitial fibrosis with increased 
left ventricular (LV) connective tissue growth factor (Ctgf) expression in the 5/6-
nephrectomized rats. In addition, our CKD model showed significantly increased white blood 
cell count and LV expression of pro-inflammatory cytokines, including interleukin-1 (IL1), 
interleukin-6 (IL6), and tumor necrosis factor-alpha (Tnf-α), indicating systemic and tissue 
inflammation. Moreover, the LV eNOS protein level was significantly reduced in our CKD 
model compared to the sham-operated group. Losartan improved the DD, LVH, and cardiac 
fibrosis and decreased the Ctgf overexpression, probably, via blocking AT1-mediated nitro-
oxidative and inflammatory mechanisms in our CKD model. Indeed, the LV expression of 
NADPH-oxidase type 4 (Nox4), inducible nitric oxide synthase (Nos2), IL1, IL6, and Tnf-α 
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was reduced, and eNOS protein level was increased in response to losartan treatment in 
uremic cardiomyopathy. In contrast, mirabegron did not prevent the development of LVH 
assessed by M-mode echocardiography and histology in CKD; however, it reduced the LV 
AT1 receptor (Agtr1a), Nox4, Nos2, and IL6 expressions in uremic cardiomyopathy. 
Interestingly, there was no significant difference between the groups in the LV β3-AR protein 
levels. Therefore, the lacking β3-AR overexpression and β3-AR-coupled activation of eNOS-
mediated pathways might be responsible for the missing antihypertrophic effects of 
mirabegron in uremic cardiomyopathy. However, mirabegron showed antifibrotic and 
moderate anti-inflammatory effects and consequently improved the DD in uremic 
cardiomyopathy. These beneficial effects of mirabegron seem to be independent of the β3-
AR-eNOS-mediated pathways and probably associated with its repressive effect on the AT1 
receptor in uremic cardiomyopathy. In our CKD model, mirabegron had adverse effects on 
glomerular function with worsening anemia, proteinuria, and serum cholesterol levels. 
Therefore, the elevated mortality risk and the possibility of future cardiovascular events might 
remain high in CKD patients treated by mirabegron. In future studies, the combination of 
mirabegron with ARBs or cholesterol-lowering drugs such as statins might be rational to 
potentiate the antiremodeling effects and prevent the adverse effects of mirabegron. 
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1.  Introduction 
The clinical syndrome of CKD is defined by abnormalities of kidney structure and/or 
deterioration of kidney function present for at least 3 months with implications for the 
individual’s health [1,2]. CKD is an emerging public health burden worldwide, affecting 1 out 
of 10 people due to the growing prevalence of its primary causes, including aging, diabetes 
mellitus, and hypertension [1,3]. In CKD, the continuous and permanent deterioration of the 
glomerular, tubular, and endocrine functions of the kidney lead to end-stage renal disease 
(ESRD). At this last stage of CKD, the glomerular filtration rate (GFR) is below 15 
mL/min/1.73 m2, and kidney replacement therapy is required for the patients’ survival [1]. As 
the number of functional nephrons declines, several systemic complications could arise. 
Deterioration in vital renal functions, such as regulation of fluid and electrolyte levels, acid-
base balance, endocrine functions affecting bone integrity or erythropoiesis, lipid metabolism, 
and blood pressure, could lead to systemic complications affecting the whole organism [1,4]. 
Notably, CKD patients have a 5- to 10-fold higher risk of developing cardiovascular diseases 
(CVDs) than the age-matched non-CKD population. Indeed, CVDs are the leading cause of 
mortality in all stages of CKD [5,6]. Moreover, CKD is recognized as an independent risk 
factor for CVDs due to its role in the development of LVH and the acceleration of 
atherosclerosis [7,8]. The CKD-associated chronic structural, functional, and 
electrophysiological remodeling of the heart is called uremic cardiomyopathy (i.e., type 4 
cardiorenal syndrome) [8–10]. In the case of type 4 cardiorenal syndrome, CKD is the 
primary disease leading to progressive cardiovascular impairment [8,10]. Uremic 
cardiomyopathy is characterized by DD, LVH, capillary rarefaction, endothelial dysfunction, 
and fibrosis in the stage of heart failure with preserved ejection fraction (HFpEF) [9,10]. Both 
preclinical and clinical studies showed that LVH could develop in CKD regardless of 
pressure- and volume-overload [11–14]. Notably, the regression of LVH was observed after 
kidney transplantation in ESRD patients [1,9,15,16]. This observation suggests that specific 
factors related to CKD itself, such as uremic toxins, contribute to the multifactorial 
pathogenesis of LVH. The prevalence of LVH significantly increases with the progression of 
CKD. Indeed, LVH is present in 50–70% of CKD patients and up to 90% in dialyzed patients 
with ESRD [5,17–19]. With the progression of CKD, cardiac fibrosis becomes more 
prominent, leading to systolic dysfunction in the phase of heart failure with reduced ejection 
fraction (HFrEF) [9,10]. Moreover, uremic cardiomyopathy markedly enhances the 
susceptibility of the heart to further injuries, including acute myocardial infarction and 
arrhythmias, meanwhile the severity and persistence of LVH are strongly correlated with 
10 
mortality risk [9,10,15]. In addition, CVDs are more commonly fatal in CKD patients than in 
the general population without CKD [20].  
Currently, there are no specific targeted therapeutic strategies available to prevent or treat 
uremic cardiomyopathy. The current cornerstone treatment options of uremic cardiomyopathy 
include drugs applied in heart failure with different etiologies and pharmaceuticals targeting 
common risk factors of CKD and CVDs (e.g., hypertension, diabetes mellitus, or 
hyperlipidemia) [10,21]. However, these standard therapeutic options mean only symptomatic 
treatments slowing down the progression of CKD. Multiple factors might contribute to the 
development of uremic cardiomyopathy; however, the precise molecular mechanisms are not 
entirely clear yet. These factors include non-CKD-specific mechanisms such as hemodynamic 
overload with over-activation of the renin-angiotensin-aldosterone system (RAAS) and 
sympathetic nervous system, hypertension, endothelial dysfunction, inflammation, and 
increased nitro-oxidative stress and CKD-specific factors such as circulating uremic toxins 
and renal anemia [9,10]. In uremic cardiomyopathy, the chronically elevated angiotensin-II 
levels might stimulate several pathological mechanisms such as inflammation, nitro-oxidative 
stress, decreased nitric oxide (NO) bioavailability via AT1 receptors, ultimately leading to 
fibrosis in the heart and kidneys [22–25]. Therefore, RAAS inhibitors, including ARBs, are 
widely used to slow down the progression of heart failure or CKD in clinical practice [25,26]. 
Indeed, losartan, a well-known and widely applied antihypertensive ARB, improved LVH and 
myocardial fibrosis in ESRD patients with hypertension [27]. Despite the broad availability of 
standard heart failure medications such as ARBs, cardiovascular morbidity and mortality 
remained high among CKD patients [9]. Therefore, the administration of novel agents that 
ameliorate or prevent the progression of uremic cardiomyopathy is urgently needed.  
In the treatment of HFpEF, enhancing NO bioavailability is considered a promising novel 
approach [28]. Mirabegron is a β3-AR agonist recently used in the clinical treatment of 
overactive bladder syndrome, improving the bladder filling capacity by relaxing the detrusor 
muscle via β3-AR [29]. In healthy heart tissue, the expression of β3-AR is considered low in 
atrial and ventricular myocytes but more abundant in non-cardiomyocytes, including 
endothelial cells [29–31]. In contrast to β1- and β2-ARs, cardiac β3-AR abundance increases 
as a counterregulatory mechanism to prevent adrenergic overactivation in chronic ischemia 
and heart failure [29,30,32–34]. In preclinical models, the β3-AR agonists attenuated cardiac 
hypertrophy and fibrosis, and improved cardiac contractility via coupling of β3-AR to the 
eNOS/cGMP pathway and activating Na+/K+-ATPase-mediated Na+ export in the 
cardiomyocytes. Moreover, the antioxidant effects of the β3-AR signaling may protect the 
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heart from elevated nitro-oxidative stress and the consecutive pro-inflammatory processes 
[29,35,36]. Belge et al. demonstrated that angiotensin-II administration did not induce cardiac 
fibrosis and hypertrophy in mice with cardiomyocyte-specific expression of human β3-AR 
[37]. It has also been described in pancreatic [38] and lung tissues [39] of male apoE knock-
out mice that chronic administration of the β3-AR agonist BRL37344 could down-regulate 
the AT1 receptors. These results suggest that chronic β3-adrenoceptor activation can regulate 
the expression of angiotensin-II receptors, and these interactions may play a protective role in 
the pancreas and lungs or other tissues such as the heart. Based on these experimental data, 
the promising therapeutic effects of the β3-AR agonist mirabegron are investigated in clinical 
trials. Currently, phase II and III clinical trials are investigating the effect of mirabegron on 
the development of LVH, HFpEF (NYHA class I-II) (Beta3_LVH trial, trial No.: 
NCT02599480), and HFrEF (NYHA class III-IV) (BEAT HF II trial, trial No.: 
NCT03926754). Notably, CKD patients are routinely excluded from clinical trials, including 
the Beta3_LVH and BEAT HF II trials. However, heart failure patients could have impaired 
renal function due to the crosstalk between the heart and kidneys in cardiorenal syndromes. 
Thus, the effects of mirabegron were not investigated in a selected patient population with 
mild to moderate uremic cardiomyopathy or in experimental CKD. Therefore, we aimed to 
compare the antiremodeling effects of the ARB losartan used in standard heart failure therapy 
and the novel β3-AR agonist mirabegron in a rat model of uremic cardiomyopathy. 
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2.  Aims of the thesis  
The present thesis aimed to compare the effects of losartan and mirabegron on routine serum 
and urine laboratory parameters, cardiac morphology and function, as well as left ventricular 
expression changes of selected genes and proteins associated with diastolic function, cardiac 




Figure 1 Primary risk factors, diagnostic criteria, and cardiovascular complications of CKD. Potential effects of losartan and 




3.  Materials and methods 
This investigation conformed to the National Institutes of Health Guide for the Care and Use 
of Laboratory Animals (NIH Publication No. 85-23, Revised 1996) and was approved by the 
Animal Research Ethics Committee of Csongrád County (XV./799/2019) and the University 
of Szeged in Hungary. All institutional and national guidelines for the care and use of 
laboratory animals were followed. The authors complied with the ARRIVE guidelines. 
 
3.1.  Animals 
In this study, a total of 45 adult male Wistar rats (Rattus norvegicus, 8 weeks old, 280-340 g) 
were housed in pairs in individually ventilated cages (Sealsafe IVC system, Tecniplast S.p.A., 
Italy). The rats were maintained with 12 h:12 h light/dark cycles in a temperature-controlled 
room throughout the study. Standard rat chow and tap water were supplied ad libitum.  
 
3.2.  Experimental setup 
Control animals underwent sham operation (n=10), and experimental CKD was induced by 
5/6th nephrectomy in two phases (n=35). After the operations, rats were followed up for 13 
weeks (Fig. 2). On the first day of the 5th follow-up week, rats were divided into the following 
four groups and treated via oral gavage daily for 8 weeks: 1) sham-operated group treated 
with per os tap water (n=10, 2 mL/kg/day), 2) CKD group treated with per os tap water 
(n=13, 2 mL/kg/day), 3) CKD group treated with per os losartan (n=12, 10 mg/kg/day 
dissolved in tap water in 2 mL/kg end volume, Arbartan 50 mg film-coated tablets, Teva 
Pharmaceutical Industries Ltd., Hungary), and 4) CKD group treated with per os mirabegron 
(n=10, 10 mg/kg/day in tap water 2 mL/kg end volume; Betmiga 50 mg prolonged-release 
tablets, Astellas Pharma Europe B.V., Netherland) (Fig. 2). In our study, 6 animals died from 
the nephrectomized groups (2 animals in the CKD group, 1 animal in the losartan-treated 
CKD group, and 3 animals in the mirabegron-treated CKD group). At weeks 4 and 12, cardiac 
morphology and function were assessed by transthoracic echocardiography (Fig. 2). Blood 
was collected from the saphenous vein at week 4 and from the abdominal aorta at week 13 to 
measure serum parameters. The animals were placed into metabolic cages (Tecniplast S.p.A., 
Italy) for 24 h at weeks 4 and 12 to measure urine volume, urine creatinine and protein levels 
(Fig. 2). At week 13, invasive blood pressure measurements were performed in a subgroup of 
animals (Fig. 2) (n=6-8). At week 13, hearts were isolated, then left ventricular samples were 
prepared for histology and biochemical measurements. The development of LVH and fibrosis 
in CKD was verified by the measurement of cardiomyocyte diameters and cross-sectional 
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areas on hematoxylin-eosin (HE)-stained slides and picrosirius red/fast green-stained (PSFG) 
slides. Total RNA was isolated from the left ventricles, and the myocardial expression of β3-
adrenergic receptor (Adrb3), angiotensinogen (Agt), Agtr1a, collagen type 1 alpha 1 chain 
(Col1a1), Ctgf, IL1, IL6, α-myosin heavy chain (Myh6), β-myosin heavy chain (Myh7), Nos2, 
Nox4, A-type natriuretic peptide (Nppa), B-type natriuretic peptide (Nppb), and peptidyl-
prolyl isomerase A (Ppia) were measured by qRT-PCR. Moreover, LV expression of β3-AR, 
eNOS, phospho-eNOS, phospholamban (PLN), phospho-PLN, and sarcoplasmic reticulum 
calcium ATPase 2a (SERCA2a) were measured by Western blot. 
 
 
Figure 2 Experimental setup. Blood: blood sampling, BP: blood pressure, CKD: chronic kidney disease, Echo: 
echocardiography, LV: left ventricle, OP: operation, qRT-PCR: quantitative real-time polymerase chain reaction, 
Urine: urine collection in metabolic cages, WB: Western blot. 
 
3.3.  5/6th nephrectomy 
Sham operation and 5/6th nephrectomy were performed in two phases as described previously 
[40,41] (Fig. 2). Briefly, anesthesia was induced by intraperitoneal injection of pentobarbital 
sodium (Euthasol, Produlab Pharma B.V., Netherlands; 40 mg/kg). At the first operation, the 
1/3 left kidney on both ends was excised. One week after the first operation, animals were 
anesthetized again, and the right kidney was removed. During sham operations, only the renal 
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capsules were removed. After the surgeries, the incision was closed with running sutures, and 
povidone-iodine was applied on the surface of the skin. As a post-operative medication, sc. 
0.3 mg/kg nalbuphine hydrochloride (Nalbuphine 10 mg/ml, Teva Pharmaceutical Industries 
Ltd., Hungary) analgesics was administered for 4 days, twice in the first two post-operative 
days and once in the third and fourth post-operative days. Enrofloxacin antibiotics (Enroxil 75 
mg tablets, Krka, Slovenia; dissolved in tap water in 3.5 mg/L end concentration) were 
administered in the drinking water for 4 days after both surgeries. 
 
3.4.  Transthoracic echocardiography 
Cardiac morphology and function were assessed by transthoracic echocardiography at weeks 
4 and 12, as we described previously [41–44] (Fig. 2). Rats were anesthetized with 2% 
isoflurane (Forane, Aesica, Queenborough Limited, UK). Two-dimensional, M-mode, 
Doppler, tissue Doppler, and 4 chamber-view images were performed by the criteria of the 
American Society of Echocardiography with a Vivid IQ ultrasound system (General Electric 
Medical Systems, USA) using a phased array 5.0–11 MHz transducer (GE 12S-RS probe). 
Data of three consecutive heart cycles were analyzed (EchoPac Dimension v201, General 
Electric Medical Systems, USA; 
https://www.gehealthcare.com/products/ultrasound/vivid/echopac) by an experienced 
investigator in a blinded manner. The mean values of three measurements were calculated and 
used for statistical evaluation. Representative M-mode images were saved from the EchoPac 
Dimension v201 software. 
 
3.5.  Blood pressure measurement 
To measure arterial blood pressure in a separated subgroup of animals, a PE50 polyethylene 
catheter (Cole-Parmer, USA) was inserted into the left femoral artery at week 13 under 
pentobarbital anesthesia (Euthasol, Produlab Pharma B.V., Netherlands; 40 mg/kg) as 
described previously [41,45]. Blood pressure measurements were performed between 09:00 
and 14:00 hours. 
 
3.6.  Serum and urine laboratory parameters 
Serum carbamide and creatinine levels were quantified by kinetic UV method using urease 
and glutamate dehydrogenase enzymes and Jaffe method, respectively. Serum sodium, 
potassium, and chloride levels were determined by indirect potentiometry using ion-selective 
electrodes. The serum calcium, magnesium, phosphate levels were quantified by complex 
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formation methods. All reagents and instruments for the serum parameter measurements were 
from Roche Diagnostics (Hoffmann-La Roche Ltd, Switzerland), as described previously 
[40,41]. Urine creatinine and urine protein levels were measured by standard laboratory 
methods as described previously [40,41]. At week 13, serum total cholesterol, HDL-
cholesterol, and triglyceride levels were measured by Roche Cobas 8000 analyzer system 
using enzymatic colorimetric assays from Roche (Hoffmann-La Roche Ltd, Switzerland) 
[46,47]. LDL-cholesterol was calculated according to the Friedewald formula. Total blood 
count and hematocrit were measured from whole blood by a hematology analyzer (XE-2100, 
Sysmex Corporation, Japan) at week 13 to verify the development of chronic systemic 
inflammation and renal anemia. 
 
3.7.  Tissue harvesting  
At week 13, hearts were isolated under pentobarbital anesthesia, and the blood was washed 
out in calcium-free Krebs-Henseleit solution. Then hearts were weighed, left and right 
ventricles were separated and weighed, and the cross-section of the left ventricle at the ring of 
the papillae was cut and fixed in 4% buffered formalin for histological analysis. Other parts of 
the left ventricles were freshly frozen in liquid nitrogen and stored at −80 °C until further 
biochemical measurements. Body weight, tibia length, left kidney weight, and lungs’ weights 
were measured at week 13. 
 
3.8.  Hematoxylin-eosin and picrosirius red and fast green staining  
Five μm paraffin-embedded transverse cut sections of the formalin-fixed subvalvular areas of 
the left ventricles were stained with HE or PSFG as described previously [41,43,44]. 
Histological slides were scanned with a Pannoramic Midi II scanner (3D-Histech, Hungary). 
On the digital HE images, cardiomyocyte diameters and cross-sectional areas were measured 
to verify the development of LVH at the cellular level. For the evaluation, the Biology Image 
Analysis Software (BIAS) was used [48]. BIAS (internal built, dated December 2019; 
https://single-cell-technologies.com/bias/) is developed by Single-Cell Technologies Ltd., 
Hungary, and the first publicly available version is expected to be released in late 2021. Image 
preprocessing was followed by deep learning-based cytoplasm segmentation. User-selected 
objects were forwarded to the feature extraction module, configurable to extract properties 
from the selected cell components. Here, transverse transnuclear cardiomyocyte diameter was 
measured in 100 selected, longitudinally oriented, mono-nucleated cardiomyocytes on left 
ventricular sections cut on the same plane. Cardiomyocyte cross-sectional areas of the same 
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cells were calculated by the software as well. Cardiac fibrosis was assessed on PSFG slides 
with an in-house developed program [41,43,44]. Representative HE- and PSFG-stained 
images were captured in Panoramic Viewer 1.15.4 (3D-Histech, Hungary; 
https://old.3dhistech.com/pannoramic_viewer). 
 
3.9.  mRNA expression profiling by qRT-PCR 
Quantitative RT-PCR was performed with gene-specific primers to monitor mRNA 
expression. RNA was isolated using QIAGEN RNeasy Fibrous Tissue Mini Kit (QIAGEN, 
Germany) from heart tissue. Then 100 μg of total RNA was reverse transcribed using iScript 
cDNA Synthesis Kit (Bio-Rad Laboratories Inc., USA). Specific primers (Adrb3: 
#qRnoCED0006313; Agt: #qRnoCED0051666; Agtr1a: #qRnoCID0052626; Col1a1: 
#qRnoCED0007857; Ctgf: #qRnoCED0001593; IL1: #qRnoCID0002056; IL6: 
#qRnoCID0053166; Myh6: #qRnoCID0001766; Myh7: #qRnoCED0001215; Nos2: 
#qRnoCID0017722; Nox4: #qRnoCID0003969; Nppa: #qRnoCED0006216; Nppb: 
#qRnoCED0001541; Ppia: #qRnoCID0056995; Tnf-α: #qRnoCED0009117) and 
SsoAdvanced Universal SYBR Green Supermix (BioRad Laboratories Inc., USA) were used 
according to the manufacturer's instructions. Ppia was used as a house keeping control gene 
for normalization. 
 
3.10.  Western blot 
Standard Western blot technique was used in the case of β3-AR with actin, eNOS, phospho-
eNOS, SERCA2a with α-tubulin, and PLN, phospho-PLN with GAPDH loading background 
as described previously [49]. Left ventricular samples (n=28) were homogenized with an 
ultrasonicator (UP100H, Hielscher Ultrasonics GmbH, Germany) in Radio-
Immunoprecipitation Assay (RIPA) buffer (50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.5% 
sodium deoxycholate, 5 mM ethylenediamine tetra-acetic acid (EDTA), 0.1% sodium dodecyl 
sulfate, 1% NP-40; Cell Signaling Technology Inc., USA) supplemented with 
phenylmethanesulfonyl fluoride (PMSF; Sigma-Aldrich, USA), sodium orthovanadate 
(Na3VO4; Sigma-Aldrich, USA) and sodium fluoride (NaF; Sigma-Aldrich, USA). The crude 
homogenates were centrifuged at 15000×g for 30 min at 4°C. After quantifying the 
supernatants’ protein concentrations using the BCA Protein Assay Kit (Pierce Thermo Fisher 
Scientific Inc., USA), 25 μg of reduced and denaturized protein was loaded. Then sodium 
dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE, 50 V, 4 h) was performed 
(6% gel in case of eNOS, phospho-eNOS, and SERCA2a, 10% gel in case of β3-AR, and 
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12% gel in case of PLN, phospho-PLN,) followed by the transfer of proteins onto a 
nitrocellulose membrane (10% methanol in case of eNOS, phospho-eNOS, and SERCA2a and 
20% methanol in case of β3-AR, PLN and phospho-PLN, 35 V, 2 h). The efficacy of transfer 
was checked using Ponceau staining. The membranes were cut vertically and horizontally into 
parts corresponding to the molecular weights of β3-AR, eNOS, phospho-eNOS, SERCA, 
PLN, phospho-PLN, GAPDH, actin, and α-tubulin. Membranes were blocked for 1 h in 5% 
(w/v) bovine serum albumin (BSA, Sigma-Aldrich, USA) supplemented with Na3VO4 and 
NaF, and were incubated with primary antibodies in the concentrations of 1:1000 against 
eNOS (#32027S, Cell Signaling Technology Inc., USA; [50]), PLN (#14562S, Cell Signaling 
Technology Inc., USA; [51]), phospho-PLN (Ser16/Thr17, #8496S, Cell Signaling 
Technology Inc., USA; [52]), SERCA2a (#4388S, Cell Signaling Technology Inc., USA; 
[53]), actin (612656, BD Bioscienses, USA; [54]) and α-tubulin (#2144S, Cell Signaling 
Technology Inc., USA; [55]) or 1:5000 against GAPDH (#2118, Cell Signaling Technology 
Inc., USA; [56]) or 1:500 against phospho-eNOS (Ser1177, #9570S, Cell Signaling 
Technology Inc., USA; [57]) and β3-AR (AB101095, Abcam PLC, UK; [58]) overnight at 
4°C in 5% BSA. Then the membranes were incubated with IRDye 800CW Goat Anti-Rabbit 
and/or IRDye 680RD Goat Anti-Mouse secondary antibody (LI-COR Biosciences, USA, in 
the concentrations of 1:5000) for 1 h at room temperature in 5% BSA to detect proteins with 
similar molecular weight on the same membrane where it is applicable. Fluorescent signals 
were detected by Odyssey CLx machine (LI-COR Biosciences, USA), and digital images 
were captured with Image Studio 5.2.5 (LI-COR Biosciences, USA; 
https://www.licor.com/bio/image-studio/). Then images were analyzed and evaluated by 
Quantity One 4.4.0 (Bio-Rad Laboratories Inc., USA; https://www.bio-rad.com/en-
hu/product/quantity-one-1-d-analysis-software?ID=1de9eb3a-1eb5-4edb-82d2-
68b91bf360fb). Representative images were exported with Image Studio 5.2.5 software. 
 
3.11.  Statistical analysis 
Statistical analysis was performed using GraphPad Prism 6.01 for Windows (GraphPad 
Software Inc., USA; https://www.graphpad.com/scientific-software/prism/). All values are 
presented as mean±S.E.M., p<0.05 was accepted as a statistically significant difference. One-
Way ANOVA was used to determine the statistical significance between all measured 
parameters within each time point. Two-way repeated-measures ANOVA was used to 
determine the effects of CKD and the treatments on serum, urine, and echocardiographic 
parameters between week 4 and endpoint follow-up data. Holm-Sidak test was used as a post 
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hoc test. In cases of phospho-eNOS/eNOS, SERCA2a, and phospho-PLN Western blot 
results, unpaired t-test was also used to investigate the statistical significance between CKD 




4.  Results 
 
4.1.  Neither losartan nor mirabegron improved the severity of CKD based on serum 
and urine parameters 
At the 4th and 12th or 13th follow-up weeks, serum and urine metabolite concentrations were 
determined to verify the development of CKD induced by 5/6th nephrectomy (Fig. 2). In this 
study, week 4 laboratory parameters confirmed that 5/6th nephrectomized animals developed 
renal failure at the same severity in each CKD group before starting the drug administrations 
(Fig. 3).  
 
 
Figure 3 The effects of losartan and mirabegron on the development of CKD in 5/6th nephrectomized rats. (a) 
Serum carbamide concentration, (b) serum creatinine concentration, (c) creatinine clearance, (d) urine creatinine 
concentration, (e) urine volume, and (f) urine protein concentration at week 4 and the endpoint. Values are 
presented as mean±S.E.M., *p < 0.05 vs. sham-operated group and #p < 0.05 vs. CKD group (n=7-10, One-Way 
ANOVA, Holm-Sidak post hoc test), $p<0.05 vs. week 4 in the same group (n=7-10, Two-ways repeated-
measures ANOVA, Holm-Sidak post hoc test). †At the endpoint, urine volume and creatinine concentration were 
measured at week 12 and serum creatinine concentration at week 13. 
 
Serum carbamide and creatinine levels were significantly increased in the 5/6th 
nephrectomized groups irrespective of losartan or mirabegron treatment compared to the 
sham-operated group at weeks 4 and 13, respectively (Fig. 3a and 3b). In the mirabegron-
treated CKD group, serum creatinine concentration was higher at the endpoint compared to 
21 
the week 4 values, suggesting a worsening renal function (Fig. 3b). Creatinine clearance 
decreased significantly in the 5/6th nephrectomized groups irrespective of losartan or 
mirabegron treatment at weeks 4 and 13 compared to the sham-operated rats at the 
corresponding follow-up timepoint, implicating an impaired renal function (Fig. 3c). At week 
4, urine creatinine concentration was significantly decreased in the 5/6th nephrectomized 
groups irrespective of treatments compared to the sham-operated group (Fig. 3d). At week 12, 
urine creatinine concentration was significantly lower in the CKD and mirabegron-treated 
CKD groups as compared to the sham-operated group (Fig. 3d). In response to losartan, the 
urine creatinine concentration was not different from the sham-operated group and showed a 
tendency of increase as compared to the CKD group (p=0.109) (Fig. 3d). In the losartan-
treated CKD group, urine creatinine concentration was significantly higher at the endpoint 
compared to the week 4 value, indicating improved creatinine excretion into the urine in 
response to losartan (Fig. 3d). At week 4, urine volumes were significantly higher in the 5/6th 
nephrectomized groups irrespective of treatments indicating the development of the polyuric 
phase of CKD (Fig. 3e). At week 12, urine volume showed a tendency of increase in the CKD 
group compared to the sham-operated group (p=0.082) (Fig. 3e). However, it was not 
significantly different between the sham-operated and the losartan-treated groups and showed 
a tendency of decrease in response to losartan as compared to the CKD group (p=0.086) (Fig. 
3e). In contrast, urine volume was not different between the CKD and mirabegron-treated 
CKD groups at week 12 (Fig. 3e). At week 4, there was no difference in the urine protein 
concentrations between the groups (Fig. 3f). At week 12, urine protein concentration was 
significantly higher in the CKD groups as compared to the sham-operated group showing an 
impaired glomerular function (Fig. 3f). At week 12, losartan did not affect, but mirabegron 
significantly increased the proteinuria compared to the CKD group, further worsening the 
glomerular function in CKD (Fig. 3f). Urine protein concentrations were significantly higher 
at week 12 than the week 4 values in the CKD groups, irrespective of losartan or mirabegron 
treatments indicating a worsening glomerular function in CKD (Fig. 3f). In the sham-operated 
group, serum carbamide concentration, creatinine clearance, and urine volume were higher at 
the endpoint as compared to the week 4 values, probably due to the growth of the animals 
(Fig. 3a, 3c, and 3e). In the CKD groups, irrespective of treatments, these parameters did not 
increase significantly at the endpoint compared to the week 4 values.  
To further characterize the severity of CKD, serum ion levels were determined at week 13 
(Table 1). There was no significant difference in the serum sodium, potassium, chloride, and 
phosphate ion levels between the groups (Table 1). Serum calcium ion concentrations were 
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significantly increased in the CKD groups irrespective of losartan- or mirabegron-treatment 
compared to the sham-operated group (Table 1). Serum magnesium ion concentrations were 
not significantly different between the CKD and the sham-operated groups (Table 1). 
Losartan did not change the serum magnesium ion concentration significantly compared to 
the CKD group (Table 1). However, serum magnesium ion concentration was significantly 
elevated in the mirabegron-treated CKD group as compared to the sham-operated or CKD 





Sham CKD CKD+losartan CKD+mirabegron 
Serum sodium ion 
(mmol/L) 
141±0.7 140±0.43 141±0.62 141±0.74 
Serum potassium ion 
(mmol/L) 
5.3±0.16 4.97±0.17 5.53±0.15 5.23±0.31 
Serum chloride ion 
(mmol/L) 
103±0.95 103±0.51 102±0.45 101±1.07 
Serum phosphate ion 
(mmol/L) 
2.28±0.15 2.31±0.1 2.22±0.06 2.46±0.13 
Serum calcium ion 
(mmol/L) 
2.44±0.01 2.54±0.04* 2.58±0.02* 2.59±0.02* 
Serum magnesium ion 
(mmol/L) 
0.9±0.02 0.97±0.04 1.03±0.04 1.29±0.12*# 
Serum total cholesterol 
(mmol/L) 
1.56±0.03 2.23±0.2* 2.65±0.12* 4.11±0.22*# 
Serum LDL-cholesterol 
(mmol/L) 
0.53±0.04 0.79±0.08* 0.73±0.03* 1.16±0.11*# 
Serum triglyceride 
(mmol/L) 
0.52±0.03 0.6±0.07 0.77±0.12 0.99±0.1*# 
Red blood cells 
(1012/L) 
8.3±0.11 7.25±0.23* 7.09±0.22* 6.55±0.32* 
Hematocrit 
(%) 
44±1 39±1* 39±1* 36±1*# 
Hemoglobin 
(g/L) 
148±2.29 131±4.2* 131±2.26* 120.14±4.58* 
White blood cells 
(109/L) 
3.45±0.23 6.63±0.87* 4.47±0.45# 6.57±0.6* 
Table 1 Serum and total blood count parameters at week 13. Values are presented as mean±S.E.M., *p < 0.05 vs. 
sham-operated group, #p < 0.05 vs. CKD group (n=6-10 for serum parameters, n=5-8 for blood count parameters, 
One-Way ANOVA, Holm-Sidak post hoc test). 
 
4.2.  Mirabegron increased the serum cholesterol level in CKD 
Serum total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglyceride levels 
were measured as cardiovascular risk factors at week 13 (Table 1). Serum total cholesterol 
and LDL-cholesterol levels elevated significantly, and serum triglyceride levels did not 
change significantly in the CKD group compared to the sham-operated group (Table 1). Both 
in the losartan- and mirabegron-treated CKD groups, total serum cholesterol, and LDL-
cholesterol levels were significantly elevated compared to the sham-operated group; however, 
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mirabegron further elevated the total cholesterol and LDL-cholesterol levels compared to the 
CKD group (Table 1). Moreover, serum triglyceride level was significantly higher in the 
mirabegron-treated CKD group as compared to sham-operated or CKD groups (Table 1).  
 
4.3.  Losartan reduced the white blood cell count, but mirabegron worsened the renal 
anemia 
Blood count parameters were determined at week 13 to characterize the severity of the 
systemic inflammation and anemia associated with CKD (Table 1). In the CKD groups, 
irrespective of losartan- or mirabegron-treatment, the red blood cell count, hematocrit, and 
hemoglobin levels were significantly decreased compared to the sham-operated group, 
indicating the development of renal anemia at week 13 (Table 1). Moreover, the hematocrit 
level was significantly lower in the mirabegron-treated CKD group compared to the CKD 
group. The white blood cell count was significantly higher in the CKD group than the sham-
operated group pointing out the development of systemic inflammation (Table 1). However, 
losartan significantly reduced the white blood cell count as compared to the CKD group 
(Table 1). Mirabegron did not change the white blood cell count in CKD (Table 1). 
 
4.4.  The systolic function remained unchanged in uremic cardiomyopathy irrespective 
of losartan or mirabegron-treatment 
Transthoracic echocardiography was performed at week 4 prior to the treatments and at week 
12 to monitor the effects of CKD and the medications on cardiac morphology and function 
(Fig. 2, Table 2, Table 3, and Fig. 4). The main systolic parameter, the ejection fraction (EF), 
was not significantly different in the sham-operated and CKD groups, irrespective of 
treatments, at weeks 4 and 12 or in the same group between weeks 4 and 12 (Fig. 4b). The 
heart rate (HR) was not significantly different between the CKD and sham-operated groups 
(Table 3). HR did not change significantly in response to losartan in CKD; however, it was 
significantly reduced by mirabegron compared to the CKD group (Table 3). The left 
ventricular end-systolic volume (LVESV), left ventricular end-diastolic volume (LVEDV), 
and stroke volume (SV) were similar in the CKD and sham-operated groups (Table 3). 
Losartan did not change the LVESV, LVEDV, and SV compared to the CKD group (Table 3). 
In contrast, the mirabegron-treated CKD group showed significantly higher LVESV and 
LVEDV compared to the sham-operated or CKD groups (Table 3). The SV was also 
significantly elevated in the mirabegron-treated CKD group compared to the CKD group, 




Sham CKD CKD+losartan CKD+mirabegron 
EF (%) 58±1 57±1 56±1 59±2 
HR (1/min) 372±8 367±12 363±11 362±12 
LVEDV (μl) 131±7 136±5 137±7 136±6 
LVESV (μl) 56±4 58±3 61±3 56±2 
SV (μl) 75±4 78±3 76±4 82±7 
CO (mL/min) 28±2 29±1 28±2 28±3 
IVCT (ms) 14.5±1.02 14.8±0.65 14.57±0.43 15.86±1.1 
IVRT (ms) 14.2±0.29 14.22±0.49 14.13±0.35 13.14±0.91 
E-velocity (m/s) 1.06±0.05 1.04±0.04 1.02±0.06 0.99±0.05 
e'-velocity (m/s) 0.05±0.003 0.05±0.003 0.05±0.004 0.05±0.003 
E/e' 20.85±1.88 22.5±2.01 21.3±1.69 19.43±2.12 
AWTs (mm) 3.2±0.1 3.35±0.13 3.31±0.14 3.35±0.09 
AWTd (mm) 1.85±0.05 1.9±0.09 1.96±0.05 1.91±0.07 
IWTs (mm) 3.31±0.11 3.41±0.2 3.42±0.13 3.35±0.19 
IWTd (mm) 1.9±0.06 1.94±0.12 1.95±0.08 1.75±0.07 
PWTs (mm) 3.51±0.11 3.59±0.15 3.47±0.1 3.49±0.1 
PWTd (mm) 2.1±0.08 2.07±0.11 1.99±0.09 1.92±0.1 
SWTs (mm) 3.37±0.1 3.4±0.13 3.5±0.03 3.49±0.08 
SWTd (mm) 1.87±0.05 1.89±0.07 1.98±0.06 1.94±0.04 
Table 2 Left ventricular morphological and functional parameters assessed by transthoracic echocardiography at 
week 4. Values are presented as mean±S.E.M. (n=8-12). 
 
However, the cardiac output (CO) was not different between the groups due to the 
compensatory effects of heart rate changes in response to the mirabegron-treatment (Table 3). 
The systolic parameter, isovolumic contraction time (IVCT), was significantly shorter in the 
CKD group as compared to the sham-operated group pointing out a mild systolic dysfunction 
in CKD (Table 3). IVCT did not change in response to losartan; however, it was significantly 
increased by mirabegron-treatment compared to the CKD group, probably due to the lower 





Sham CKD CKD+losartan CKD+mirabegron 
HR (1/min) 361±9 386±9 383±13 332±4# 
LVEDV (μl) 275±12 262±19 262±17 368±33*# 
LVESV (μl) 124±8 120±10 107±11 181±26*# 
SV (μl) 152±11 142±10 161±9 181±8# 
CO (mL/min) 55±4 55±4 61±4 60±3 
IVCT (ms) 13.3±0.67 10.8±0.59* 12.22±0.66 14.43±0.61# 
IVRT (ms) 14.3±0.72 11.7±0.47* 12.78±0.43 14.71±1.15# 
E-velocity (m/s) 0.97±0.03 1.02±0.05 1.06±0.04 1.06±0.06 
E/e’ 19.45±1.28 28.21±2.66* 22.82±1.55 22.88±1.39 
AWTs (mm) 3.19±0.1 3.65±0.09* 3.41±0.05 3.56±0.1* 
AWTd (mm) 1.96±0.03 2.17±0.04* 1.98±0.04# 2.24±0.11* 
IWTs (mm) 3.01±0.11 3.69±0.1* 3.32±0.13 3.51±0.29 
IWTd (mm) 1.82±0.06 2.18±0.05* 1.92±0.06# 1.99±0.19 
SBP (mmHg) 145±4 166±13 142±4 170±9 
DBP (mmHg) 104±2 122±10 102±3 127±6 
MBP (mmHg) 119±3 139±11 117±3 144±8 
Table 3 Left ventricular morphological and functional parameters assessed by transthoracic echocardiography at 
week 12 and blood pressure values at week 13. Values are presented as mean±S.E.M., *p < 0.05 vs. sham-operated 
group and #p < 0.05 vs. CKD group (n=7-10 for echocardiography and n=6-8 for blood pressure parameters, One-
Way ANOVA, Holm-Sidak post hoc test).  
 
4.5.  Both losartan and mirabegron ameliorated the diastolic dysfunction in uremic 
cardiomyopathy 
The diastolic parameter, isovolumic relaxation time (IVRT) was significantly shorter in the 
CKD group as compared to the sham-operated group (Table 3). In response to losartan 
treatment, IVRT was not different from the CKD or sham-operated groups (Table 3). 
Mirabegron-treatment significantly increased the IVRT as compared to the CKD group (Table 
3). However, another diastolic parameter, the mitral valve early flow velocity (E) was not 
significantly different between the groups (Table 3). A sensitive parameter of the diastolic 
function, the septal mitral annulus velocity (e’), was significantly decreased in the CKD group 
in contrast to the sham-operated group indicating the development of DD in CKD (Fig. 4c). 
The e’ velocity was significantly increased by losartan and mirabegron compared to the CKD 
group (Fig. 4c). E/e’ ratio was significantly higher in the CKD group than the sham-operated 
group, which is another indicator of the DD (Table 3). In response to losartan or mirabegron, 
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the E/e’ ratio was not significantly different from the sham-operated group (Table 3). In the 
sham-operated group, e’ was not significantly different at weeks 4 and 12 (Fig. 4c). In the 
CKD group, e’ was significantly decreased at week 12 as compared to the week 4 value, 
verifying the progression of diastolic dysfunction in uremic cardiomyopathy. (Fig. 4c). Both 
in the losartan and mirabegron-treated groups, e’ did not change at week 12 as compared to 
week 4 values, proving that both drugs prevented the progression of DD (Fig. 4c).  
 
 
Figure 4 The effects of losartan and mirabegron on the echocardiographic parameters at week 13. (a) 
Representative M-mode images, (b) ejection fraction (EF), (c) diastolic septal mitral annulus velocity (e’), (d) 
posterior wall thicknesses in systole (PWTs) and (e) diastole (PWTd), (f) septal wall thickness in systole (SWTs) 
and (g) diastole (SWTd). Values are presented as mean±S.E.M., *p < 0.05 vs. sham-operated group, #p < 0.05 vs. 
CKD group (n=7-10, One-Way ANOVA, Holm-Sidak post hoc test), $p<0.05 vs. week 4 in the same group (n=7-
10, Two-ways repeated-measures ANOVA, Holm-Sidak post hoc test). 
 
4.6.  Losartan but not mirabegron ameliorated the echocardiographic signs of left 
ventricular hypertrophy in CKD 
Four weeks after the operations, there was no significant difference in any cardiac 
morphologic parameters between the groups (Table 2 and Fig. 4d-4g). At week 12, systolic 
and diastolic anterior, inferior, posterior, and septal wall thicknesses were significantly 
increased in response to CKD, indicating the development of a concentric LVH (Fig. 4d-4g 
27 
and Table 3). Losartan significantly reduced the diastolic anterior, inferior, posterior, and 
septal, as well as the systolic posterior wall thicknesses compared to the CKD group (Fig. 4d, 
4e, 4g, and Table 3). Losartan did not change the systolic anterior, inferior, and septal wall 
thicknesses significantly (Fig. 4f and Table 3). In contrast, mirabegron failed to significantly 
reduce the wall thicknesses in uremic cardiomyopathy (Fig 4d-4g and Table 3). There was no 
significant difference in the sham-operated group at week 4 and 12 values in cardiac 
morphology (Fig. 4d-4g). In the CKD group, the systolic and diastolic septal wall thicknesses 
were significantly increased at week 12 as compared to the week 4 values, verifying the 
progression of LVH (Fig. 4f and 4g). In the losartan-treated CKD group, systolic and diastolic 
septal wall thicknesses did not increase at week 12 compared to the week 4 values, pointing 
out that losartan prevented the development of LVH (Fig. 4f and 4g). In contrast, in the 
mirabegron-treated group, systolic and diastolic wall thicknesses were significantly higher at 
week 12 than the week 4 values, proving that mirabegron failed to prevent the progression of 
LVH (Fig. 4f and 4g). In CKD, hypertension is a well-known complication and an 
independent risk factor for the development of LVH. In our study, the systolic, diastolic, and 
mean arterial blood pressure values were not statistically different between the groups at week 
13 (Table 3).  
 
4.7.  Losartan but not mirabegron reduced the left ventricular weight in uremic 
cardiomyopathy 
At week 13, hearts, lungs, left kidneys, and tibias were isolated, then left and right ventricles 
were separated, and the organ weights and tibia lengths were measured (Table 4). There was 
no significant difference in body weight, tibia length, right ventricular weight between the 
groups (Table 4). However, LV weight showed a significant increase in the CKD group 
compared to the sham-operated group indicating the macroscopic signs of LVH (Table 4). 
Losartan but not mirabegron significantly decreased the heart weight and LV weight 
compared to the CKD group supporting the echocardiographic results (Table 3, Table 4, and 
Fig. 4). The remnant left kidney weight was markedly higher in the CKD group than the 
whole left kidney weight in the sham-operated group, pointing out a compensatory renal 
hypertrophy in CKD (Table 4). In response to losartan, the remnant left kidney weight was 
not different from the sham-operated or the CKD groups (Table 4). Mirabegron did not reduce 
the remnant left kidney weight in CKD (Table 4). Lung weight was not significantly different 
between the CKD and the sham-operated groups (Table 4). In response to losartan, lung 
weight was not different from the sham-operated and CKD groups (Table 4). In contrast, the 
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mirabegron-treated CKD group showed significantly higher lung weights as compared to the 





Sham CKD CKD+losartan CKD+mirabegron 
Body weight  
(g) 
454±10 466±10 454±13 459±18 
Tibia length 
(cm) 
4.2±0.03 4.25±0.03 4.22±0.04 4.26±0.04 
Right ventricular weight 
(mg) 
198±7 201±6 190±9 206±14 
Heart weight 
(mg) 
1161±40 1251±25 1118±20# 1335±84 
Left ventricular weight 
(mg) 
811±23 898±19* 774±14# 961±19* 
Left kidney weight 
(mg) 
1313±55 1647±90* 1492±62 1749±146* 
Lung weight 
(mg) 
1620±29 1693±37 1666±49 1828±90* 
Table 4 Body weight, tibia length, and organ weights at week 13. Values are presented as mean±S.E.M., *p < 0.05 
vs. sham-operated group, #p < 0.05 vs. CKD group (n=7-10, One-Way ANOVA, Holm-Sidak post hoc test). 
 
4.8.  Losartan but not mirabegron attenuated cardiomyocyte hypertrophy in CKD 
Cardiomyocyte diameters and cross-sectional areas were measured on hematoxylin-eosin-
stained histological slides to verify the development of LVH assessed by echocardiography 
and autopsy. Cardiomyocytes showed a significantly enlarged diameter and cross-sectional 
area in the CKD group compared to the sham-operated group, confirming the development of 
LVH at the cellular level (Fig. 5a-5d). Losartan but not mirabegron treatment significantly 
reduced the cardiomyocyte diameter and cross-sectional area in CKD, validating the 
echocardiographic and macroscopic findings (Fig. 5a-5d). To strengthen our results at the 
molecular level, the expression of cardiac hypertrophy markers was measured by qRT-PCR. 
The increased ratio of the fetal myosin heavy chain β-isoform to the adult α-isoform (β-MHC 
to α-MHC ratio) is an indicator of the fetal gene reprogramming in LVH in response to tissue 
hypoxia [60]. The LV mRNA expression of α-MHC (Myh6) and β-MHC (Myh7) isoforms, as 
well as their ratio, failed to change significantly in the CKD group as compared to the sham-
operated group, suggesting a slowdown phase in the LVH development at week 13 (Table 5). 
Losartan but not mirabegron significantly reduced the LV expression of the β-MHC isoform 
(Myh7) and the β-MHC to α-MHC ratio compared to the CKD group (Table 5). In contrast, 
mirabegron significantly reduced the α-MHC isoform (Myh6) compared to the CKD or sham-




Figure 5 The effects of losartan and mirabegron on the cardiomyocyte hypertrophy and interstitial fibrosis 
assessed by histology at week 13. (a) Representative haematoxylin-eosin (HE)-stained slides at 100x and (c) 40x 
magnification, (b) cardiomyocyte diameters and (d) cross-sectional areas, (e) representative picrosirius red and 
fast green (PSFG)-stained slides at 20x magnification, (f) left ventricular collagen content. Scale bars represent 20 
µm at the 100x magnified images, 50 µm at the 40x magnified images, and 100 µm at the 20x magnified images. 
Values are presented as mean±S.E.M., *p < 0.05 vs. sham-operated group, #p < 0.05 vs. CKD group. (n=7-10, 
One-Way ANOVA, Holm-Sidak post hoc test).  
 
4.9. Both losartan and mirabegron attenuated the left ventricular fibrosis in CKD 
The development of left ventricular fibrosis in CKD was investigated by quantifying 
picrosirius red and fast green stained slides. Significant interstitial fibrosis was found in the 
CKD group compared to the sham-operated group (Fig. 5e and 5f). Losartan treatment 
significantly decreased the left ventricular fibrosis compared to the CKD group, probably, due 
to its well-known antiremodeling effects by blocking the AT1 receptor. Collagen deposition 
was not significantly different in the mirabegron-treated CKD group as compared to the 
sham-operated group; however, it showed a trend toward a decrease as compared to the CKD 
group (p=0.067) (Fig. 5e and 5f). To further strengthen our results, the LV expression of 
fibrosis and heart failure markers were measured by qRT-PCR. In the CKD group, the LV 
expression of the collagen type I alpha 1 (Col1a1) failed to increase significantly as compared 
to the sham-operated group. However, another fibrosis marker in the angiotensin-II/tissue 
growth factor-beta (TGF-β) pathway, the connective tissue growth factor (Ctgf) was up-
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regulated significantly compared to the sham-operated group, indicating an active fibrotic 
process in CKD at week 13 (Table 5). Neither losartan nor mirabegron reduced the LV 
expression of Col1a1 significantly as compared to the CKD or sham-operated groups; 
however, it showed a tendency of decrease in the mirabegron-treated CKD group as compared 
to the CKD group. Ctgf showed significant repression in response to losartan as compared to 
the CKD group (Table 5). In contrast, Ctgf was significantly overexpressed in the mirabegron-
treated CKD group compared to the CKD or the sham-operated groups (Table 5). These 
results also point out that mirabegron might ameliorate cardiac fibrosis via Ctgf-independent 
mechanisms in uremic cardiomyopathy. The left ventricular expression of the heart failure 
markers A-type and B-type natriuretic peptides (Nppa and Nppb, respectively) were not 
significantly different between the CKD and sham-operated groups, indicating that the CKD 
animals are rather in a compensated heart failure stage (Table 5). Losartan but not 
mirabegron-treatment resulted in a significant LV repression of Nppa and Nppb compared to 
the CKD group (Table 5). 
 
4.10.  Both losartan and mirabegron repressed the cardiac inflammatory and nitro-
oxidative stress markers in uremic cardiomyopathy at the transcript level 
Inflammatory processes triggered by elevated nitro-oxidative stress are major contributors to 
the development of uremic cardiomyopathy. The overexpression of the superoxide anion 
producing nicotinamide adenine dinucleotide phosphate-oxidase (NADPH-oxidase or Nox) 
isoforms and inducible nitric oxide synthase (iNOS or Nos2) are major sources of elevated 
nitro-oxidative stress in the heart [10]. In the CKD group, LV Nox4 expression showed a 
statistically non-significant increase by 35% (p=0.078), and Nos2 expression increased 
significantly compared to the sham-operated group (Table 5). Both losartan and mirabegron 
treatment significantly reduced the LV Nox4 and Nos2 expression compared to the CKD or 
sham-operated groups (Table 5). The LV expressions of the inflammatory cytokines 
interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-α (Tnf-α) were 
significantly increased in the CKD group as compared to the sham-operated group, indicating 
tissue inflammation (Table 5). Both losartan and mirabegron caused significant repression in 
the IL-6 mRNA levels compared to the CKD group (Table 5). Furthermore, losartan but not 
mirabegron decreased the expression of IL-1 and Tnf-α significantly as compared to the CKD 
group (Table 5). Angiotensin-II is known to increase the nitro-oxidative stress and 
inflammation via AT1 (Agtr1a) receptors by increasing NADPH-oxidase levels and 
inflammatory markers such as IL-6 and TNF-α [62]. Interestingly, LV Agtr1a was 
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significantly repressed in the CKD group compared to the sham-operated group, probably as a 
compensatory mechanism of the chronically over-activated RAAS in CKD (Table 5). The 
losartan-treated CKD group showed no significant difference in the LV Agtr1a expression 
compared to the CKD or sham-operated groups. However, mirabegron-treatment significantly 
decreased the LV Agtr1a expression as compared to CKD or sham-operated groups (Table 5). 
There was no significant difference in the LV angiotensinogen (Agt) expression at the mRNA 





Sham CKD CKD+losartan CKD+mirabegron 
Myh6/Ppia 1.41±0.07 1.23±0.11 1.21±0.07 0.76±0.09*# 
Myh7/Ppia 1.29±0.1 1.27±0.18 0.71±0.12*# 1.01±0.14 
Myh7/Myh6 0.94±0.09 1.26±0.15 0.61±0.13# 1.32±0.31 
Col1a1/Ppia 0.2±0.05 0.32±0.08 0.25±0.04 0.19±0.06 
Ctgf/Ppia 0.93±0.09 1.32±0.15* 0.82±0.08# 1.91±0.24*# 
Nppa/Ppia 0.42±0.09 0.63±0.15 0.24±0.02# 0.56±0.05 
Nppb/Ppia 1.05±0.15 1.23±0.11 0.64±0.09# 1.19±0.16 
Nox4/Ppia 1.75±0.18 2.38±0.20 0.57±0.09*# 1.25±0.13*# 
Nos2/Ppia 0.95±0.19 2.80±0.55* 1.26±0.21# 1.17±0.37# 
IL1/Ppia 0.77±0.05 1.18±0.11* 0.78±0.06# 0.94±0.16 
IL6/Ppia 0.81±0.18 2.94±0.6* 0.37±0.08# 0.52±0.12# 
Tnf-α/Ppia 0.77±0.05 1.2±0.1* 0.83±0.09# 0.99±0.12 
Agtr1a/Ppia 1.55±0.06 1.13±0.1* 1.26±0.11 0.86±0.08*# 
Agt/Ppia 1.32±0.09 1.24±0.09 1.08±0.12 1.12±0.14 
Adrb3/Ppia 0.65±0.10 0.99±0.07 0.9±0.1 1.08±0.21 
Table 5 qRT-PCR results at week 13. Values are presented as mean±S.E.M., *p < 0.05 vs. sham-operated group, 
#p < 0.05 vs. CKD group (n=6-10, One-Way ANOVA, Holm-Sidak post hoc test). Ppia was used as a 
housekeeping gene for normalization. 
 
4.11.  β3-AR expression did not increase in uremic cardiomyopathy irrespective of 
losartan or mirabegron-treatment 
Myocardial overexpression of the β3-AR was reported in heart failure of different etiology 
[29]. LV β3-AR (Adrb3) mRNA expression showed only an increasing tendency in the CKD 
group compared to the sham-operated group if analyzed by One-Way ANOVA in the four 
groups (Table 5). Notably, if only the sham-operated and the CKD groups were compared by 
unpaired t-test, the left ventricular β3-AR mRNA expression was significantly increased in 
32 
the CKD group compared to the sham-operated group (0.99±0.07 vs. 0.65±0.10 relative gene 
expression, p=0.012). However, β3-AR protein levels failed to increase in the CKD group 
compared to the sham-operated group (Fig. 6a). Neither losartan nor mirabegron changed the 
β3-AR mRNA or protein levels significantly in uremic cardiomyopathy (Table 5, Fig. 6a). 
 
Figure 6 The effects of losartan and mirabegron on the protein expression at week 13 assessed by Western blot. 
Left ventricular expression and representative images of (a) beta-3 adrenergic receptor (β3-AR), (b) endothelial 
nitric oxide synthase (eNOS), (c) phospho-eNOS (p-eNOS), (d) phospho-eNOS/ eNOS ratio, (e) 
sarcoendoplasmic reticulum calcium ATPase 2a (SERCA2a), (f) phospholamban (PLN), (g) phospho-PLN 
(pPLN), and (h) phospho-PLN/PLN ratio. Values are presented as mean±S.E.M., *p < 0.05 vs. sham-operated 
group, #p < 0.05 vs. CKD group (n=6-7, One-Way ANOVA, Holm-Sidak post hoc test). 
. 
4.12.  Losartan but not mirabegron increased the eNOS protein level in uremic 
cardiomyopathy. 
Decreased activity of eNOS and NO bioavailability are considered major contributors to 
HFpEF and uremic cardiomyopathy [63,64]. Accordingly, the LV expression of eNOS protein 
was significantly decreased in the CKD group compared to the sham-operated group in our 
model (Fig. 6b). Losartan treatment significantly increased the eNOS level; however, 
mirabegron treatment could not increase it (Fig. 6b). Phospho-eNOS protein level was 
significantly increased, but phospho-eNOS/eNOS ratio did not increase significantly in the 
33 
CKD group compared to the sham-operated group (Fig. 6c and 6d). Phospho-eNOS levels 
were not significantly different in losartan or mirabegron-treated CKD groups compared to 
the sham-operated group and were significantly decreased compared to the CKD group (Fig. 
6c). There was no significant difference in the phospho-eNOS/eNOS ratio among the groups 
(Fig. 6d). 
 
4.13.  No changes in SERCA2a and phospholamban protein levels in uremic 
cardiomyopathy irrespective of losartan or mirabegron-treatment 
Decreased SERCA2a expression and disturbed calcium homeostasis are related to impaired 
diastolic relaxation and declining systolic function [65]. In contrast, the SERCA2a protein 
level was not different in the experimental groups in our present study (Fig. 6e). The 
phosphorylation of PLN can increase the SERCA activity and improve the speed of muscle 
relaxation [65]. However, there was no difference in the PLN expressions between the groups 
(Fig. 6f). Notably, phospho-PLN protein levels showed a tendency of decrease in the CKD 
and mirabegron-treated CKD groups compared to the sham-operated group (p=0.157 and 
p=0.137, respectively, unpaired t-test) (Fig. 6g). There was no significant difference in 
phospho-PLN protein level between the losartan-treated CKD and sham-operated or CKD 
groups (Fig. 6g). The phospho-PLN/PLN ratios did not decrease in the CKD group, and 




5.  Discussion 
In the 5/6th nephrectomized rats, uremic cardiomyopathy developed with similar laboratory 
and cardiac alterations to those in CKD-induced HFpEF patients. Our present study 
demonstrates first that there is no difference in the left ventricular β3-AR expression at the 
protein level in the HFpEF phase of uremic cardiomyopathy in rats. Here we also demonstrate 
for the first time in the literature that the β3-AR agonist mirabegron has no antihypertrophic 
but mild antifibrotic and anti-inflammatory effects in uremic cardiomyopathy, which seems to 
be independent of the β3-AR coupled eNOS-mediated pathways and might be explained by 
its effect causing repression on AT1 receptor in uremic cardiomyopathy. The ARB losartan 
significantly ameliorated the development of uremic cardiomyopathy via antihypertrophic, 
antifibrotic, anti-inflammatory, and eNOS-associated mechanisms.  
Our present findings on the characteristic laboratory and echocardiographic parameters in 
CKD are consistent with the literature data and our previous results in 5/6th nephrectomized 
rats [40,41,66,67]. Our previous study showed no significant differences in the baseline 
laboratory and echocardiographic results between the sham-operated and CKD animals [41]. 
Therefore, we did not characterize the baseline (i.e., preoperative) laboratory and 
echocardiographic parameters in our present study. In this study, week 4 laboratory 
parameters confirmed that 5/6th nephrectomized animals developed renal failure at the same 
severity in each CKD group before starting the drug administrations. We have found here 
characteristic laboratory changes in CKD, including increased serum urea and creatinine 
concentrations, increased urine protein levels, and decreased creatinine clearance 13 weeks 
after the operations. Moreover, renal anemia, hypercalcemia, and hypercholesterolemia 
developed in the 5/6th nephrectomized animals. In our CKD model, echocardiography 
confirmed the presence of uremic cardiomyopathy characterized by LVH and DD. Histology 
confirmed LVH at the cellular level and revealed LV fibrosis. According to these findings, the 
severity of CKD in our model corresponds to the human G2 or G3a CKD stages with mildly 
or moderately decreased kidney function [7,21]. Notably, severe hypertension is usually not a 
feature of the 5/6th nephrectomy-induced CKD models [67]. Indeed, our CKD model showed 
only a tendency of increase in blood pressure values. Therefore, DD might be developed due 
to LVH and fibrosis without severe hypertension.  
Both preclinical and clinical studies showed that CKD-specific and non-specific risk factors 
such as uremic toxins, renal anemia, the over-activation of the RAAS and sympathetic 
nervous system, elevated nitro-oxidative stress, decreased NO levels, increased systemic and 
tissue inflammation could provoke the development of uremic cardiomyopathy [10,15]. 
35 
Indeed, our CKD model showed significantly elevated white blood cell count and 
overexpressed pro-inflammatory cytokines, including IL1, IL6, and Tnf-α in the left ventricle, 
indicating systemic and tissue inflammation. The interplay of increased nitro-oxidative stress 
and inflammation can be an essential contributor to LVH in CKD [5,10,15] and was linked to 
the progression of HFpEF [64]. NADPH oxidases (NOX), producing superoxide anion, may 
also be involved in the development of cardiac hypertrophy, interstitial fibrosis or contractile 
dysfunction [68]. Accordingly, LV Nox4 expression showed a statistically non-significant 
increase in our CKD model. Reduced NO bioavailability due to increased superoxide levels 
and consequential peroxynitrite formation might contribute to cardiomyocyte stiffness and 
fibrosis, leading to diastolic dysfunction and microvascular endothelial dysfunction in HFpEF 
and uremic cardiomyopathy [69]. Our CKD model showed a decreased myocardial eNOS 
protein level, probably, due to the capillary rarefaction and hypertrophy in CKD, and a 
significantly elevated eNOS phosphorylation on the main activation site (Ser1177). The latter 
could be a compensatory mechanism to increase NO production in uremic cardiomyopathy. 
Accordingly, the phospho-eNOS/eNOS ratio was tendentiously increased in CKD as 
compared to the sham operated-group. Our results on eNOS expression and activity in uremic 
cardiomyopathy are in line with the literature data [70]. Furthermore, eNOS uncoupling leads 
to ROS/RNS production instead of NO, increasing the nitro-oxidative stress and hypertrophic 
remodeling [69,71]. According to studies using animal models and human myocardial 
samples, the up-regulation of iNOS (i.e., Nos2) can contribute to the dysregulation of NO 
production in oxidative and pro-inflammatory states leading to increased peroxynitrite 
production, which can be associated with pathologic cardiac remodeling [64,71]. Indeed, in 
our present study, Nos2 expression was significantly increased in uremic cardiomyopathy. On 
the other hand, eNOS-derived NO production was demonstrated to enhance LV relaxation via 
PLN-mediated SERCA Ca2+ re-uptake [63]. Decreased SERCA2a expression and disturbed 
calcium homeostasis could also be associated with impaired relaxation and declining systolic 
function in later stages of HF [65]. In contrast, Silveira et al. found that SERCA2a and its 
regulator PLN did not decrease in early isolated diastolic dysfunction induced by aortic 
stenosis [72]. Primessnig et al. demonstrated in 5/6th-nephrectomy-induced CKD in rats that 
reduced phosphorylation of PLN could lead to reduced SERCA activity 8 weeks after the 
operation. However, they found increased PLN phosphorylation 24 weeks after the operation, 
pointing out the time-dependency of PLN phosphorylation and SERCA activity in uremic 
cardiomyopathy [73]. In our study, there was no significant change in SERCA2a and PLN 
expressions 13 weeks after the operations in CKD. These results might be explained by the 
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longer follow-up time in our study than the 8-week follow-up period used in the study of 
Primessnig et al. [73]. Losartan and mirabegron did not change the SERCA expression and 
phospho-PLN/PLN expressions in CKD, suggesting that these proteins did not play a crucial 
role in the effects causing improved diastolic function in the losartan and mirabegron-treated 
groups. 
Most of the standard therapies in uremic cardiomyopathy are supportive and used to modulate 
comorbidities or heart failure slowing down the progression of the condition [21,74]. RAAS 
inhibitors, including ARBs, are cornerstone therapies to reduce proteinuria, CKD progression, 
and cardiovascular risk [75]. The ARB losartan was reported to ameliorate LVH and 
myocardial fibrosis development and improve cardiac function in 5/6th nephrectomized rats 
and ESRD patients [27,76]. In our present study, losartan failed to improve the main routine 
laboratory parameters of kidney function, including creatinine clearance, serum carbamide, 
and creatinine levels. However, it reduced the urine volume and the remnant kidney weight 
compared to the CKD group showing a mild renoprotective effect. The further histological or 
molecular examination of the kidneys was out of the scope of the present study.  
Evidence suggests that chronic over-activation of the RAAS and the sympathetic nervous 
system in HF also stimulates the inflammatory processes and increases nitro-oxidative stress, 
further aggravating each other [77,78]. Angiotensin-II has been reported to activate cardiac 
NADPH-oxidase via AT1 receptor and, subsequently, the over-production of ROS/RNS. The 
increased nitro-oxidative stress could trigger the production of pro-inflammatory mediators, 
such as IL1, IL6, TNF-α, and TGF-β [78,79], and the inflammatory cytokines could decrease 
eNOS expression and NO bioavailability, contributing to cardiac remodeling and HF [62]. 
Therefore, AT1 blockade by losartan is a rational therapeutic option to ameliorate cardiac 
remodeling by reducing nitro-oxidative stress, inflammatory processes and improve NO 
bioavailability in uremic cardiomyopathy. Indeed, in our present study, losartan improved the 
DD, LVH, and cardiac fibrosis, probably via blocking the AT1 receptor-mediated nitro-
oxidative (Nox4 and Nos2) and inflammatory (IL1, IL6, and Tnf-α) as well as via eNOS-
associated mechanisms in our CKD model. Interestingly, it has been reported that another 
ARB, valsartan combined with the neprilysin inhibitor sacubitril (LCZ696), attenuated 
cardiac hypertrophy and fibrosis in 5/6th nephrectomized rats [80] and currently human phase 
I clinical trials are observing the effect of sacubitril/valsartan on advanced CKD patients with 
HF (NYHA class II-IV) (trial No.: NCT03771729 and NCT04218435). Taken together, our 
present results are in line with the literature data on the antiremodeling effects of ARBs in 
uremic cardiomyopathy.  
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Modulation of NO signaling is considered one of the novel promising approaches in HFpEF 
treatment [28,71]. β3-AR agonists are reported to ameliorate cardiac remodeling, diastolic and 
systolic dysfunction via the β3-AR receptor coupled eNOS-derived NO production beyond 
other mechanisms such as preserving the function of the Na+/K+-ATP-ase, antioxidant effects 
via the AKT-NO-mPTP signaling, and influencing the fatty acid metabolism [29,69,71,81]. 
Currently, the aforementioned Beta3_LVH and BEAT HF II clinical trials are investigating 
the antiremodeling effects of the β3-AR agonist mirabegron on the development of LVH, 
HFpEF and HFrEF. Notably, kidney function is often decreased in HFpEF and HFrEF 
patients, and chronic heart failure aggravates renal dysfunction mutually. This bidirectional 
interaction of renal and heart failure is the key concept in cardiorenal syndrome [7,8,82,83]. 
Dysfunction of each organ can induce and perpetuate injury in the other via complex 
hemodynamic, neurohormonal, and biochemical pathways such as over-activated RAAS and 
sympathetic nervous system, increased nitro-oxidative stress, and inflammatory pathways 
[10]. Notably, patients with uncontrolled hypertension, severe anemia, moderately or severely 
decreased renal function (eGFR<30 or 50 mL/min corresponding to G3b-G5 CKD stages, 
respectively) were excluded from the Beta3_LVH and BEAT HF II clinical trials. Thus, to 
our best knowledge, the antiremodeling effects of mirabegron were not investigated in a 
selected patient population suffering from uremic cardiomyopathy. Considering the exclusion 
criteria of the aforementioned clinical trials, we aimed to investigate the effects of mirabegron 
in mild to moderate experimental uremic cardiomyopathy. In our study, mirabegron did not 
affect the major parameters of renal function, including serum carbamide and creatinine 
levels, creatinine clearance, and urine volume at the endpoint. However, it had several adverse 
effects on glomerular function, worsening the proteinuria, renal anemia, serum total 
cholesterol, and LDL-cholesterol levels in our CKD model. Although mirabegron repressed 
the left ventricular IL6 level, white blood cell count remained elevated, suggesting the 
presence of low-grade systemic inflammation in CKD irrespective of mirabegron-treatment.  
In our present study, mirabegron could not prevent the development of left ventricular 
hypertrophy assessed by M-mode echocardiography and histology in CKD. We speculate that 
the failing β3-AR overexpression and the β3-AR-coupled activation of eNOS-mediated 
pathways are responsible for its missing antihypertrophic effects in CKD. Notably, if only the 
sham-operated and CKD groups were compared by unpaired t-test, the left ventricular β3-AR 
mRNA expression was significantly increased in the CKD group compared to the sham-
operated group (p=0.012, Table 5). However, the protein level showed no difference between 
the groups (p=0.336, Fig. 6a). This could be explained by i) increased degradation and 
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turnover rate of proteins in CKD as it is considered as a catabolic state [84], and ii) the β3-AR 
expression could be regulated time-dependently in uremic cardiomyopathy. We also measured 
the left ventricular β3-AR mRNA and protein levels at an earlier follow-up time point in the 
same 5/6 nephrectomy-induced CKD model in male Wistar rats 9 weeks after the operations 
[85]. At this time, HFpEF is also developed, as we described previously [41]. At this earlier 
follow-up time point, the left ventricular expression of β3-AR mRNA was also significantly 
increased in the CKD group as compared to the sham-operated group, and there was no 
significant change in the β3-AR protein level between the groups, similarly to the week 13 
findings [85]. However, it could not be excluded that the β3-AR protein expression might 
change in a later phase of uremic cardiomyopathy. Notably, Miao et al. demonstrated in aortic 
banding-induced heart failure in rats that the cardiac expression of β3-AR mRNA and protein 
expressions in myocardial tissues showed a positive correlation with aging and the severity of 
heart failure [86]. 
Additionally, the precise mechanisms and functional role of the β3-AR in heart failure 
induced by different cardiovascular diseases, including diabetes mellitus, acute myocardial 
infarction, or chemotherapy-induced heart failure forms, are also not fully discovered. Most 
studies investigating the effects of β3-AR agonists in heart failure demonstrated that β3-AR 
agonists attenuated cardiac hypertrophy and fibrosis and improved cardiac contractility via 
coupling of β3-AR to the eNOS/cGMP pathway as the main mechanism [29,81]. Therefore, 
we also investigated the left ventricular expression of eNOS, phospho-eNOS, and their ratio 
in our study. Mirabegron did not increase the total eNOS level and significantly decreased the 
phospho-eNOS level as compared to the CKD group. Therefore, it seems that the β3-AR is 
uncoupled from eNOS or unable to activate it, probably, due to elevated nitro-oxidative stress, 
inflammatory mechanisms, and uremic toxins-induced alterations [70]. The precise 
mechanistic characterization of CKD-induced changes of the β3-AR-mediated pathways was 
out of the scope of the present study.  
However, in our present study, mirabegron had beneficial effects on DD characterized by e’ 
and E/e’, and cardiac fibrosis assessed by histology and left ventricular expressions of 
Col1a1. We hypothesized that mirabegron could have its antiremodeling effects 
independently of the β3-AR-eNOS-mediated pathway in uremic cardiomyopathy. 
Interestingly, mirabegron reduced the left ventricular expression of the AT1 receptor in 
uremic cardiomyopathy. This finding is particularly interesting since the chronic 
administration of the β3-AR agonists BRL37344 could down-regulate the AT1 receptor 
expression and up-regulate the AT2 receptor expression in the pancreatic [38] and lung tissues 
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[39] of male apoE knock-out mice. Interestingly, Belge et al. demonstrated that angiotensin-II 
administration did not induce cardiac fibrosis and hypertrophy in mice with cardiomyocyte-
specific expression of human β3-AR [37]. Recently, Kamiya et al. demonstrated that chronic 
infusion of a β3-adrenergic receptor agonist attenuated cardiac fibrosis and improved diastolic 
dysfunction independently of blood pressure in an angiotensin-II-induced heart failure model 
with hypertension in mice [87]. These results suggest that chronic β3-adrenoceptor activation 
regulates the expression of angiotensin-II receptor types, and these interactions may play a 
protective role in the lung, pancreatic, and other tissues such as the heart. The chronic over-
activation of the AT1 receptor could play a major role in oxidative stress, inflammation, and 
ultimately fibrosis in the development of heart failure [88,89]. Indeed, in our present study, 
mirabegron significantly reduced the left ventricular expression of the nitro-oxidative stress 
markers Nox4 and Nos2 and the inflammatory marker IL6 in uremic cardiomyopathy. Our 
present results are in line with these literature data since mirabegron treatment significantly 
reduced the AT1 receptor expression in uremic cardiomyopathy, which might lead to its 
antioxidant, anti-inflammatory, and antifibrotic effects independently of the eNOS/cGMP-
mediated pathway in uremic cardiomyopathy. Moreover, Hadi et al. demonstrated the dual 
antioxidant role of β3-ARs in macrophages: i) β3-AR decreases ROS production by directly 
inhibiting NADPH-oxidase activity; and ii) β3-AR induces the expression of catalase, a major 
hydrogen peroxide scavenger [88]. They also confirmed that β3-AR stimulation inhibited the 
ROS-dependent nuclear factor kappa-light-chain-enhancer of activated B cell (NF-κB) 
inflammatory pathway in the uterus [88]. In another study, β3-AR stimulation inhibited 
cytokine production, including TNF-α and IL6, to prevent myometrial cell apoptosis and 
extracellular matrix remodeling [89]. However, these secondary antioxidant and anti-
inflammatory mechanisms of the β3-AR induction by mirabegron are not well-characterized 
in HF. Our present finding on the antiremodeling effects of mirabegron independently of β3-
AR-eNOS mediated pathways could be interesting for physicians treating heart failure 
patients with reduced renal function since mirabegron could have antifibrotic effects in the 
early stages of uremic cardiomyopathy. Therefore, the involvement of early-stage CKD 
patients in clinical studies investigating the effects of mirabegron could be considered in the 
future. However, mirabegron had adverse effects on glomerular function with worsening 
anemia, proteinuria, and serum cholesterol levels in our CKD model. Therefore, the elevated 
mortality risk and the possibility of future cardiovascular events might remain high in CKD 
patients treated by mirabegron. In future studies, the combination of mirabegron with ARBs 
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or cholesterol-lowering drugs such as statins might be rational to potentiate the 
antiremodeling effects and prevent the adverse effects of mirabegron. 
Similar to all experimental investigations, our study is not without limitations. Uremic 
cardiomyopathy is a unique entity most commonly manifested as left ventricular hypertrophy 
with preserved ejection fraction and predisposing the heart for further cardiovascular 
complications in CKD [90]. However, there are still many unknown mechanisms, such as the 
exact role of β3-AR in the development of uremic cardiomyopathy. We demonstrated that 
there is no difference in the left ventricular β3-AR expression at the protein level 13 weeks 
after the 5/6th nephrectomy in rats. However, it could not be excluded that the β3-AR protein 
expression might change in a later HFrEF phase of uremic cardiomyopathy. The time-
dependent and mechanistic investigation of the cardiac β3-AR expression in the development 
of uremic cardiomyopathy was out of the scope of the present study. Notably, the precise 
mechanisms and functional role of the β3-AR in heart failure induced by different 
cardiovascular diseases, including diabetes mellitus, acute myocardial infarction, or 
chemotherapy-induced heart failure forms, are also not fully discovered. Therefore, we 
focused mainly on the potential protective effects of mirabegron in CKD, investigating the 
well-known markers of uremic cardiomyopathy and the effects caused by mirabegron. The 
deep mechanistic insight of the antiremodeling effects of mirabegron was out of the scope of 
our present descriptive study. We found here moderate antiremodeling effects of mirabegron 
and hypothesized that mirabegron could have antifibrotic effects in uremic cardiomyopathy 
independently of the β3-AR-eNOS-mediated pathway, but probably associated with its effects 
causing repression on the AT1 receptor. However, further mechanistic studies are needed to 
explore the antiremodeling effects of mirabegron in uremic cardiomyopathy. 
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6.  Conclusions 
The purpose of this study was to evaluate and compare the effects of chronic administration of 
ARB losartan and β3-AR agonist mirabegron on cardiac remodeling, function, and the 
development of HFpEF in uremic cardiomyopathy in rats. In summary, our present study 
suggests that the development of uremic cardiomyopathy might be prevented or markedly 
slowed down by losartan if its administration starts in early CKD stages without manifest 
LVH. In contrast, mirabegron failed to improve the severity of LVH, but had several 
beneficial effects on diastolic dysfunction, fibrosis, and tissue inflammation in uremic 
cardiomyopathy. These antiremodeling effects seem to be independent of the β3-AR/eNOS 
mediated pathways in uremic cardiomyopathy and are probably associated with the effects of 
mirabegron downregulating the AT1 receptor. In the future, these beneficial effects of 
mirabegron can be used as an “add-on” therapy to enhance the effectiveness of the primary 
medication against cardiac remodeling.  
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Comparison of the antiremodeling 
effects of losartan and mirabegron 
in a rat model of uremic 
cardiomyopathy
Zsuzsanna Z. A. Kovács1, Gergő Szűcs1, Marah Freiwan1, Mónika G. Kovács1, 
Fanni M. Márványkövi1, Hoa Dinh1, Andrea Siska2, Katalin Farkas2, Ferenc Kovács3,4, 
András Kriston3,4, Péter Horváth3,4,5, Bence Kővári6, Bálint Gábor Cserni6, Gábor Cserni6, 
Imre Földesi2, Tamás Csont 1* & Márta Sárközy 1*
Uremic cardiomyopathy is characterized by diastolic dysfunction (DD), left ventricular hypertrophy 
(LVH), and fibrosis. Angiotensin-II plays a major role in the development of uremic cardiomyopathy 
via nitro-oxidative and inflammatory mechanisms. In heart failure, the beta-3 adrenergic receptor 
(β3-AR) is up-regulated and coupled to endothelial nitric oxide synthase (eNOS)-mediated pathways, 
exerting antiremodeling effects. We aimed to compare the antiremodeling effects of the angiotensin-II 
receptor blocker losartan and the β3-AR agonist mirabegron in uremic cardiomyopathy. Chronic 
kidney disease (CKD) was induced by 5/6th nephrectomy in male Wistar rats. Five weeks later, rats 
were randomized into four groups: (1) sham-operated, (2) CKD, (3) losartan-treated (10 mg/kg/
day) CKD, and (4) mirabegron-treated (10 mg/kg/day) CKD groups. At week 13, echocardiographic, 
histologic, laboratory, qRT-PCR, and Western blot measurements proved the development of 
uremic cardiomyopathy with DD, LVH, fibrosis, inflammation, and reduced eNOS levels, which were 
significantly ameliorated by losartan. However, mirabegron showed a tendency to decrease DD and 
fibrosis; but eNOS expression remained reduced. In uremic cardiomyopathy, β3-AR, sarcoplasmic 
reticulum ATPase (SERCA), and phospholamban levels did not change irrespective of treatments. 
Mirabegron reduced the angiotensin-II receptor 1 expression in uremic cardiomyopathy that might 
explain its mild antiremodeling effects despite the unchanged expression of the β3-AR.
Chronic kidney disease (CKD) is a global health problem affecting 1 out of 10 people due to the growing preva-
lence of its primary causes, including aging, diabetes mellitus, and  hypertension1,2. CKD patients have a five- to 
tenfold higher risk for developing cardiovascular diseases compared to the age-matched non-CKD  population3. 
The CKD-associated chronic structural, functional, and electrophysiological remodeling of the heart is called 
uremic cardiomyopathy (i.e., type 4 cardiorenal syndrome)4,5. It is characterized by diastolic dysfunction (DD), 
left ventricular hypertrophy (LVH), capillary rarefaction, endothelial dysfunction, and fibrosis in the stage of 
heart failure with preserved ejection fraction (HFpEF)5,6. With the progression of CKD, cardiac fibrosis becomes 
more prominent, leading to systolic dysfunction in the phase of heart failure with reduced ejection fraction 
(HFrEF)5,6. Moreover, uremic cardiomyopathy markedly enhances the susceptibility of the heart to further 
injuries, including acute myocardial infarction and  arrhythmias5–7. Therefore, cardiovascular diseases are more 
commonly fatal in CKD patients than in the general population without  CKD8.
Multiple factors might contribute to the development of uremic cardiomyopathy; however, the precise 
molecular mechanisms are not entirely clear. These factors include non-CKD-specific mechanisms such as 
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hemodynamic overload with over-activation of the renin–angiotensin–aldosterone system (RAAS) and sympa-
thetic nervous system, hypertension, endothelial dysfunction, inflammation, and increased nitro-oxidative stress 
and CKD-specific factors such as circulating uremic toxins and renal  anemia5,6. In uremic cardiomyopathy, the 
chronically elevated angiotensin-II levels might stimulate several pathological mechanisms such as inflammation, 
nitro-oxidative stress, decreased NO bioavailability via angiotensin-II type 1 receptors (AT1), ultimately leading 
to fibrosis both in the heart and  kidneys9–12. Therefore, RAAS inhibitors, including angiotensin-II receptor block-
ers (ARBs), are widely used to slow down heart failure and CKD progression in clinical  practice12,13. Despite the 
broad availability of standard heart failure medications such as ARBs, cardiovascular morbidity and mortality 
among CKD patients remained  high5. Therefore, using novel agents that ameliorate or prevent the progression 
of uremic cardiomyopathy is urgently needed.
Mirabegron is a β3-AR agonist recently used in the clinical treatment of overactive bladder  syndrome14. 
In healthy heart tissue, the expression of β3-AR is considered low in atrial and ventricular myocytes but more 
abundant in non-cardiomyocytes, including endothelial  cells14–16. In contrast to β1- and β2-ARs, cardiac β3-AR 
abundance increases as a counterregulatory mechanism to prevent chronic adrenergic overactivation in chronic 
ischemia and heart  failure14,15,17–19. In pre-clinical models, the β3-AR agonists attenuated cardiac hypertrophy 
and fibrosis and improved cardiac contractility via coupling of β3-AR to the eNOS/cGMP pathway and activat-
ing  Na+/K+-ATPase-mediated  Na+ export in the cardiomyocytes. Moreover, the antioxidant effects of the β3-AR 
signaling may protect the heart from elevated nitro-oxidative stress and the consecutive pro-inflammatory 
 processes14,20,21. Belge et al. demonstrated that angiotensin-II administration did not induce cardiac fibrosis and 
hypertrophy in mice with cardiomyocyte-specific expression of human β3-AR22. It has also been described in 
 pancreatic23 and lung  tissues24 of male apoE knock-out mice that chronic administration of the β3-AR agonist 
BRL37344 could down-regulate the AT1 receptors. These results suggest that chronic β3-adrenoceptor activation 
can regulate the expression of angiotensin-II receptors, and these interactions may play a protective role in the 
pancreas and lungs or other tissues such as the heart.
Therefore, the antiremodeling effects of the β3-AR agonist mirabegron are investigated in HFpEF and HFrEF 
patients in clinical trials. However, late-stage CKD patients are routinely excluded from clinical trials. Thus, 
the effects of mirabegron were not investigated in a selected patient population with mild to moderate uremic 
cardiomyopathy or in experimental CKD. Therefore, our present study aimed to compare the antiremodeling 
effects of the ARB losartan used in standard heart failure therapy and the novel β3-AR agonist mirabegron in 
uremic cardiomyopathy in rats.
Results
Neither losartan nor mirabegron improved the severity of CKD based on serum and urine 
parameters. At the 4th and 12th or 13th follow-up weeks, serum and urine metabolite concentrations were 
determined to verify the development of CKD induced by 5/6th nephrectomy (Fig. 1). Serum carbamide and 
creatinine levels were significantly increased in the 5/6th nephrectomized groups irrespective of losartan or 
mirabegron treatment compared to the sham-operated group at weeks 4 and 13, respectively (Fig. 2a,b). In the 
mirabegron-treated CKD group, serum creatinine concentration was higher at the endpoint compared to the 
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week 4 values, suggesting a worsening renal function (Fig. 2b). Creatinine clearance decreased significantly in 
the 5/6th nephrectomized groups irrespective of losartan or mirabegron treatment at weeks 4 and 13 compared 
to the sham-operated rats at the corresponding follow-up timepoint, implicating an impaired renal function 
(Fig. 2c). At week 4, urine creatinine concentration was significantly decreased in the 5/6th nephrectomized 
groups irrespective of treatments compared to the sham-operated group (Fig. 2d). At week 12, urine creatinine 
concentration was significantly lower in the CKD and mirabegron-treated CKD groups as compared to the 
sham-operated group (Fig. 2d). In response to losartan, the urine creatinine concentration was not different 
from the sham-operated group and showed a tendency of increase as compared to the CKD group (p = 0.109) 
(Fig.  2d). In the losartan-treated CKD group, urine creatinine concentration was significantly higher at the 
endpoint compared to the week 4 value, indicating improved creatinine excretion into the urine in response 
to losartan (Fig. 2d). At week 4, urine volumes were significantly higher in the 5/6th nephrectomized groups 
irrespective of treatments indicating the development of the polyuric phase of CKD (Fig. 2e). At week 12, urine 
volume showed a tendency of increase in the CKD group compared to the sham-operated group (p = 0.082) 
(Fig. 2e). However, it was not significantly different between the sham-operated and the losartan-treated groups 
and showed a tendency of decrease in response to losartan as compared to the CKD group (p = 0.086) (Fig. 2e). 
In contrast, urine volume was not different between the CKD and mirabegron-treated CKD groups at week 12 
(Fig. 2e). At week 4, there was no difference in the urine protein concentrations between the groups (Fig. 2f). 
At week 12, urine protein concentration was significantly higher in the CKD groups as compared to the sham-
operated group showing an impaired glomerular function (Fig. 2f). At week 12, losartan did not affect, but mira-
begron significantly increased the proteinuria compared to the CKD group, further worsening the glomerular 
function in CKD (Fig. 2f). Urine protein concentrations were significantly higher at week 12 than the week 4 
values in the CKD groups, irrespective of losartan or mirabegron treatments indicating a worsening glomerular 
function in CKD (Fig. 2f). In the sham-operated group, serum carbamide concentration, creatinine clearance, 
and urine volume were higher at the endpoint as compared to the week 4 values, probably due to the growth 
Figure 2.  The effects of losartan and mirabegron on the development of CKD in 5/6th nephrectomized rats. 
(a) Serum carbamide concentration, (b) serum creatinine concentration, (c) creatinine clearance, (d) urine 
creatinine concentration, (e) urine volume, and (f) urine protein concentration at week 4 and the endpoint. 
Values are presented as mean ± S.E.M., *p < 0.05 vs. sham-operated group and #p < 0.05 vs. CKD group (n = 7–10, 
One-Way ANOVA, Holm-Sidak post hoc test), $p < 0.05 vs. week 4 in the same group (n = 7–10, Two-ways 
repeated-measures ANOVA, Holm-Sidak post hoc test). Sham sham-operated group, CKD chronic kidney 
disease group, CKD + L losartan-treated chronic kidney disease group, CKD + M mirabegron-treated chronic 
kidney disease group. Creatinine clearance was calculated according to the standard formula (urine creatinine 
concentration [μM] × urine volume for 24 h [mL])/(serum creatinine concentration [μM] × 24 × 60 min). †At 
the endpoint, urine volume and creatinine concentration were measured at week 12 and serum creatinine 
concentration at week 13.
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of the animals (Fig. 2a,c,e). In the CKD groups, irrespective of treatments, these parameters did not increase 
significantly at the endpoint compared to the week 4 values.
To further characterize the severity of CKD, serum ion levels were determined at week 13 (Table 1). There 
was no significant difference in the serum sodium, potassium, chloride, and phosphate ion levels between the 
groups (Table 1). Serum calcium ion concentrations were significantly increased in the CKD groups irrespec-
tive of losartan- or mirabegron-treatment compared to the sham-operated group (Table 1). Serum magnesium 
ion concentrations were not significantly different between the CKD and the sham-operated groups (Table 1). 
Losartan did not change the serum magnesium ion concentration significantly compared to the CKD group 
(Table 1). However, serum magnesium ion concentration was significantly elevated in the mirabegron-treated 
CKD group as compared to the sham-operated or CKD groups (Table 1).
Mirabegron increased the serum cholesterol level in CKD. Serum total cholesterol, low-density 
lipoprotein (LDL) cholesterol, and triglyceride levels were measured as cardiovascular risk factors at week 13 
(Table 1). Serum total cholesterol and LDL-cholesterol levels elevated significantly, and serum triglyceride lev-
els did not change significantly in the CKD group compared to the sham-operated group (Table 1). Both in 
the losartan- and mirabegron-treated CKD groups, total serum cholesterol, and LDL-cholesterol levels were 
significantly elevated compared to the sham-operated group; however, mirabegron further elevated the total 
cholesterol and LDL-cholesterol levels compared to the CKD group (Table 1). Moreover, serum triglyceride level 
was significantly higher in the mirabegron-treated CKD group as compared to sham-operated or CKD groups 
(Table 1).
Losartan reduced the white blood cell count, but mirabegron worsened the renal ane-
mia. Blood count parameters were determined at week 13 to characterize the severity of the systemic inflam-
mation and anemia associated with CKD (Table 1). In the CKD groups, irrespective of losartan- or mirabegron-
treatment, the red blood cell count, hematocrit, and hemoglobin levels were significantly decreased compared 
to the sham-operated group, indicating the development of renal anemia at week 13 (Table 1). Moreover, the 
hematocrit level was significantly lower in the mirabegron-treated CKD group compared to the CKD group. The 
white blood cell count was significantly higher in the CKD group than the sham-operated group pointing out 
the development of systemic inflammation (Table 1). However, losartan significantly reduced the white blood 
cell count as compared to the CKD group (Table 1). Mirabegron did not change the white blood cell count in 
CKD (Table 1).
The systolic function remained unchanged in uremic cardiomyopathy irrespective of losar-
tan or mirabegron-treatment. Transthoracic echocardiography was performed at week 4 prior to the 
treatments and at week 12 to monitor the effects of CKD and the medications on cardiac morphology and 
function (Figs. 1 and 3a–g). The main systolic parameter, the ejection fraction (EF), was not significantly differ-
ent in the sham-operated and CKD groups, irrespective of treatments, at weeks 4 and 12 or in the same group 
between weeks 4 and 12 (Fig. 3b). The heart rate (HR) was not significantly different between the CKD and 
sham-operated groups (Table 2). HR did not change significantly in response to losartan in CKD; however, it 
was significantly reduced by mirabegron compared to the CKD group (Table 2). The left ventricular end-systolic 
volume (LVESV), left ventricular end-diastolic volume (LVEDV), and stroke volume (SV) were similar in the 
CKD and sham-operated groups (Table 2). Losartan did not change the LVESV, LVEDV, and SV compared to the 
Table 1.  Serum and total blood count parameters at week 13. Values are presented as mean ± S.E.M., *p < 0.05 
vs. sham-operated group, #p < 0.05 vs. CKD group (n = 6–10 for serum parameters, n = 5–8 for blood count 




Sham CKD CKD + losartan CKD + mirabegron
Serum sodium ion (mmol/L) 141 ± 0.7 140 ± 0.43 141 ± 0.62 141 ± 0.74
Serum potassium ion (mmol/L) 5.3 ± 0.16 4.97 ± 0.17 5.53 ± 0.15 5.23 ± 0.31
Serum chloride ion (mmol/L) 103 ± 0.95 103 ± 0.51 102 ± 0.45 101 ± 1.07
Serum phosphate ion (mmol/L) 2.28 ± 0.15 2.31 ± 0.1 2.22 ± 0.06 2.46 ± 0.13
Serum calcium ion (mmol/L) 2.44 ± 0.01 2.54 ± 0.04* 2.58 ± 0.02* 2.59 ± 0.02*
Serum magnesium ion (mmol/L) 0.9 ± 0.02 0.97 ± 0.04 1.03 ± 0.04 1.29 ± 0.12*#
Serum total cholesterol (mmol/L) 1.56 ± 0.03 2.23 ± 0.2* 2.65 ± 0.12* 4.11 ± 0.22*#
Serum LDL-cholesterol (mmol/L) 0.53 ± 0.04 0.79 ± 0.08* 0.73 ± 0.03* 1.16 ± 0.11*#
Serum triglyceride (mmol/L) 0.52 ± 0.03 0.6 ± 0.07 0.77 ± 0.12 0.99 ± 0.1*#
Red blood cells  (1012/L) 8.3 ± 0.11 7.25 ± 0.23* 7.09 ± 0.22* 6.55 ± 0.32*
Hematocrit (%) 44 ± 1 39 ± 1* 39 ± 1* 36 ± 1*#
Hemoglobin (g/L) 148 ± 2.29 131 ± 4.2* 131 ± 2.26* 120.14 ± 4.58*
White blood cells  (109/L) 3.45 ± 0.23 6.63 ± 0.87* 4.47 ± 0.45# 6.57 ± 0.6*
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CKD group (Table 2). In contrast, the mirabegron-treated CKD group showed significantly higher LVESV and 
LVEDV compared to the sham-operated or CKD groups (Table 2). The SV was also significantly elevated in the 
mirabegron-treated CKD group compared to the CKD group, probably due to the positive inotropic effects of 
mirabegron via β1-ARs25 (Table 2). However, the cardiac output (CO) was not different between the groups due 
to the compensatory effects of heart rate changes in response to the mirabegron-treatment (Table 2). The sys-
tolic parameter, isovolumic contraction time (IVCT), was significantly shorter in the CKD group as compared 
to the sham-operated group pointing out a mild systolic dysfunction in CKD (Table 2). IVCT did not change 
in response to losartan; however, it was significantly increased by mirabegron-treatment compared to the CKD 
group, probably due to the lower heart rate in the mirabegron-treated CKD group (Table 2).
Both losartan and mirabegron ameliorated the diastolic dysfunction in uremic cardiomyopa-
thy. The diastolic parameter, isovolumic relaxation time (IVRT) was significantly shorter in the CKD group 
as compared to the sham-operated group (Table 2). In response to losartan-treatment, IVRT was not different 
from the CKD or sham-operated groups (Table 2). Mirabegron-treatment significantly increased the IVRT as 
compared to the CKD group (Table 2). However, another diastolic parameter, the mitral valve early flow velocity 
(E) was not significantly different between the groups (Table 2). A sensitive parameter of the diastolic function, 
the septal mitral annulus velocity (e’), was significantly decreased in the CKD group in contrast to the sham-
operated group indicating the development of DD in CKD (Fig. 3c). The e’ velocity was significantly increased 
by losartan and mirabegron compared to the CKD group (Fig. 3c). E/e’ ratio was significantly higher in the CKD 
group than the sham-operated group, which is another indicator of the DD (Table 2). In response to losartan or 
Figure 3.  The effects of losartan and mirabegron on the echocardiographic parameters at week 13. (a) 
Representative M-mode images, (b) ejection fraction (EF), (c) diastolic septal mitral annulus velocity (e’), (d) 
posterior wall thicknesses in systole (PWTs) and (e) diastole (PWTd), (f) septal wall thickness in systole (SWTs) 
and (g) diastole (SWTd). Values are presented as mean ± S.E.M., *p < 0.05 vs. sham-operated group, #p < 0.05 vs. 
CKD group (n = 7–10, One-Way ANOVA, Holm-Sidak post hoc test), $p < 0.05 vs. week 4 in the same group 
(n = 7–10, Two-ways repeated-measures ANOVA, Holm-Sidak post hoc test). Sham sham-operated group, CKD 
chronic kidney disease group, CKD + L losartan-treated chronic kidney disease group, CKD + M mirabegron-
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mirabegron, the E/e’ ratio was not significantly different from the sham-operated group (Table 2). In the sham-
operated group, e’ was not significantly different at weeks 4 and 12 (Fig. 3c). In the CKD group, e’ was signifi-
cantly decreased at week 12 as compared to the week 4 value, verifying the progression of diastolic dysfunction 
in uremic cardiomyopathy. (Fig. 3c). Both in the losartan and mirabegron-treated groups, e’ did not change at 
week 12 as compared to week 4 values, proving that both drugs prevented the progression of DD (Fig. 3c).
Losartan but not mirabegron ameliorated the echocardiographic signs of left ventricular 
hypertrophy in CKD. Four weeks after the operations, there was no significant difference in any cardiac 
morphologic parameters between the groups (Fig. 3d–g and Supplementary Table S1). At week 12, systolic and 
diastolic anterior, inferior, posterior, and septal wall thicknesses were significantly increased in response to CKD, 
indicating the development of a concentric LVH (Fig. 3d–g and Table 2). Losartan significantly reduced the 
diastolic anterior, inferior, posterior, and septal, as well as the systolic posterior wall thicknesses compared to 
the CKD group (Fig.  3d,e,g, and Table  2). Losartan did not change the systolic anterior, inferior, and septal 
wall thicknesses significantly (Fig. 3f and Table 2). In contrast, mirabegron failed to significantly reduce the 
wall thicknesses in uremic cardiomyopathy (Fig. 3d–g and Table 2). There was no significant difference in the 
sham-operated group at week 4 and 12 values in cardiac morphology (Fig. 3d–g). In the CKD group, the systolic 
and diastolic septal wall thicknesses were significantly increased at week 12 as compared to the week 4 values, 
verifying the progression of LVH (Fig. 3f,g). In the losartan-treated CKD group, systolic and diastolic septal wall 
thicknesses did not increase at week 12 compared to the week 4 values, pointing out that losartan prevented the 
development of LVH (Fig. 3f,g). In contrast, in the mirabegron-treated group, systolic and diastolic wall thick-
nesses were significantly higher at week 12 than the week 4 values, proving that mirabegron failed to prevent the 
progression of LVH (Fig. 3f,g). In CKD, hypertension is a well-known complication and an independent risk 
factor for the development of LVH. In our study, the systolic, diastolic, and mean arterial blood pressure values 
were not statistically different between the groups at week 13 (Table 2).
Losartan but not mirabegron reduced the left ventricular weight in uremic cardiomyopa-
thy. At week 13, hearts, lungs, left kidneys, and tibias were isolated, then left and right ventricles were sepa-
rated, and the organ weights and tibia lengths were measured (Supplementary Table S2). There was no significant 
difference in body weight, tibia length, right ventricular weight between the groups (Supplementary Table S2). 
However, LV weight showed a significant increase in the CKD group compared to the sham-operated group 
indicating the macroscopic signs of LVH (Supplementary Table S2). Losartan but not mirabegron significantly 
decreased the heart weight and LV weight compared to the CKD group supporting the echocardiographic results 
(Supplementary Table S2, Table 2, and Fig. 3). The remnant left kidney weight was markedly higher in the CKD 
Table 2.  Left ventricular morphological and functional parameters assessed by transthoracic 
echocardiography at week 12 and blood pressure values at week 13. Values are presented as mean ± S.E.M., 
*p < 0.05 vs. sham-operated group and #p < 0.05 vs. CKD group (n = 7–10 for echocardiography and n = 6–8 for 
blood pressure parameters, One-Way ANOVA, Holm-Sidak post hoc test). Sham sham-operated group, CKD 
chronic kidney disease group, AWTd diastolic anterior wall thickness, AWTs systolic anterior wall thickness 
CO cardiac output, DBP diastolic blood pressure, E-velocity early ventricular filling velocity, e’-velocity diastolic 
septal mitral annulus velocity, HR heart rate, IVCT isovolumic contraction time, IVRT isovolumic relaxation 
time, IWTd diastolic inferior wall thickness, IWTs systolic inferior wall thickness, LVEDV left ventricular end-
diastolic volume, LVESV left ventricular end-systolic volume, MBP mean arterial blood pressure, SBP systolic 
blood pressure, SV stroke volume.
Parameter (unit)
Groups
Sham CKD CKD + losartan CKD + mirabegron
HR (1/min) 361 ± 9 386 ± 9 383 ± 13 332 ±  4#
LVEDV (μl) 275 ± 12 262 ± 19 262 ± 17 368 ± 33*#
LVESV (μl) 124 ± 8 120 ± 10 107 ± 11 181 ± 26*#
SV (μl) 152 ± 11 142 ± 10 161 ± 9 181 ±  8#
CO (mL/min) 55 ± 4 55 ± 4 61 ± 4 60 ± 3
IVCT (ms) 13.3 ± 0.67 10.8 ± 0.59* 12.22 ± 0.66 14.43 ± 0.61#
IVRT (ms) 14.3 ± 0.72 11.7 ± 0.47* 12.78 ± 0.43 14.71 ± 1.15#
E-velocity (m/s) 0.97 ± 0.03 1.02 ± 0.05 1.06 ± 0.04 1.06 ± 0.06
E/e’ 19.45 ± 1.28 28.21 ± 2.66* 22.82 ± 1.55 22.88 ± 1.39
AWTs (mm) 3.19 ± 0.1 3.65 ± 0.09* 3.41 ± 0.05 3.56 ± 0.1*
AWTd (mm) 1.96 ± 0.03 2.17 ± 0.04* 1.98 ± 0.04# 2.24 ± 0.11*
IWTs (mm) 3.01 ± 0.11 3.69 ± 0.1* 3.32 ± 0.13 3.51 ± 0.29
IWTd(mm) 1.82 ± 0.06 2.18 ± 0.05* 1.92 ± 0.06# 1.99 ± 0.19
SBP (mmHg) 145 ± 4 166 ± 13 142 ± 4 170 ± 9
DBP (mmHg) 104 ± 2 122 ± 10 102 ± 3 127 ± 6
MBP (mmHg) 119 ± 3 139 ± 11 117 ± 3 144 ± 8
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group than the whole left kidney weight in the sham-operated group, pointing out a frank compensatory renal 
hypertrophy in CKD (Table S2). In response to losartan, the remnant left kidney weight was not different from 
the sham-operated or the CKD groups (Supplementary Table S2). Mirabegron did not reduce the remnant left 
kidney weight in CKD (Supplementary Table S2). Lung weight was not significantly different between the CKD 
and the sham-operated groups (Supplementary Table S2). In response to losartan, lung weight was not different 
from the sham-operated and CKD groups (Supplementary Table S2). In contrast, the mirabegron-treated CKD 
group showed significantly higher lung weights as compared to the sham-operated group suggesting the pres-
ence of pulmonary edema (Supplementary Table S2).
Losartan but not mirabegron attenuated cardiomyocyte hypertrophy in CKD. Cardiomyocyte 
diameters and cross-sectional areas were measured on hematoxylin–eosin-stained histological slides to verify 
the development of LVH assessed by echocardiography and autopsy. Cardiomyocytes showed a significantly 
enlarged diameter and cross-sectional area in the CKD group compared to the sham-operated group, confirm-
ing the development of LVH at the cellular level (Fig. 4a–d). Losartan but not mirabegron treatment significantly 
reduced the cardiomyocyte diameter and cross-sectional area in CKD, validating the echocardiographic and 
macroscopic findings (Fig. 4a–d). To strengthen our results at the molecular level, the expression of cardiac 
hypertrophy markers was measured by qRT-PCR. The increased ratio of the fetal myosin heavy chain β-isoform 
to the adult α-isoform (β-MHC to α-MHC ratio) is an indicator of the fetal gene reprogramming in LVH in 
Figure 4.  The effects of losartan and mirabegron on left ventricular hypertrophy and fibrosis assessed 
by histology at week 13. (a) Representative haematoxylin–eosin (HE)-stained slides at 100 × and (c) 
40 × magnification, (b) cardiomyocyte diameters and (d) cross-sectional areas, (e) representative picrosirius red 
and fast green (PSFG)-stained slides at 20 × magnification, (f) left ventricular collagen content. On the digital 
HE images, cardiomyocyte diameters and cross-sectional areas were measured in 100 selected cardiomyocytes 
on left ventricular sections cut on the same plane. The mean values of the collagen content of 10 representative 
PSFG-stained images were calculated and used for statistical evaluation in the case of each left ventricular slide. 
Scale bars represent 20 µm at the 100 × magnified images, 50 µm at the 40 × magnified images, and 100 µm at 
the 20 × magnified images. Values are presented as mean ± S.E.M., *p < 0.05 vs. sham-operated group, #p < 0.05 
vs. CKD group. (n = 7–10, One-Way ANOVA, Holm-Sidak post hoc test). Sham sham-operated group, CKD 
chronic kidney disease group, CKD + L losartan-treated chronic kidney disease group, CKD + M mirabegron-
treated chronic kidney disease group. Representative HE- or PSFG-stained slides were captured in the 
Panoramic Viewer 1.15.4 software.
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response to tissue  hypoxia26. The LV mRNA expression of α-MHC (Myh6) and β-MHC (Myh7) isoforms, as well 
as their ratio, failed to change significantly in the CKD group as compared to the sham-operated group, suggest-
ing a slowdown phase in the LVH development at week 13 (Table 3). Losartan but not mirabegron significantly 
reduced the LV expression of the β-MHC isoform (Myh7) and the β-MHC to α-MHC ratio compared to the 
CKD group (Table 3). In contrast, mirabegron significantly reduced the α-MHC isoform (Myh6) compared to 
the CKD or sham-operated groups (Table 3), probably, due to its negative inotropic  effects27.
Both losartan and mirabegron attenuated the left ventricular fibrosis in CKD. The development 
of left ventricular fibrosis in CKD was investigated by quantifying picrosirius red and fast green stained slides. 
Significant interstitial fibrosis was found in the CKD group compared to the sham-operated group (Fig. 4e,f). 
Losartan treatment significantly decreased the left ventricular fibrosis compared to the CKD group, probably, 
due to its well-known antiremodeling effects by blocking the AT1 receptor. Collagen deposition was not sig-
nificantly different in the mirabegron-treated CKD group as compared to the sham-operated group; however, it 
showed a trend toward a decrease as compared to the CKD group (p = 0.067) (Fig. 4e,f). To further strengthen 
our results, the LV expression of fibrosis and heart failure markers were measured by qRT-PCR. In the CKD 
group, the LV expression of the collagen type I alpha 1 (Col1a1) failed to increase significantly as compared to 
the sham-operated group. However, another fibrosis marker in the angiotensin-II/TGF-β pathway, the connec-
tive tissue growth factor (Ctgf) was up-regulated significantly compared to the sham-operated group, indicating 
an active fibrotic process in CKD at week 13 (Table 3). Neither losartan nor mirabegron reduced the LV expres-
sion of Col1a1 significantly as compared to the CKD or sham-operated groups; however, it showed a tendency of 
decrease in the mirabegron-treated CKD group as compared to the CKD group. Ctgf showed significant repres-
sion in response to losartan as compared to the CKD group (Table 3). In contrast, Ctgf was significantly over-
expressed in the mirabegron-treated CKD group compared to the CKD or the sham-operated groups (Table 3). 
These results also point out that mirabegron might ameliorate cardiac fibrosis via Ctgf-independent mecha-
nisms in uremic cardiomyopathy. The left ventricular expression of the heart failure markers A-type and B-type 
natriuretic peptides (Nppa and Nppb, respectively) were not significantly different between the CKD and sham-
operated groups, indicating that the CKD animals are rather in a compensated heart failure stage (Table 3). 
Losartan but not mirabegron-treatment resulted in a significant LV repression of Nppa and Nppb compared to 
the CKD group (Table 3).
Both losartan and mirabegron repress the cardiac inflammatory and nitro-oxidative stress 
markers in uremic cardiomyopathy at the transcript level. Inflammatory processes triggered by 
elevated nitro-oxidative stress are major contributors to the development of uremic cardiomyopathy. The over-
expression of the superoxide anion producing nicotinamide adenine dinucleotide phosphate-oxidase (NADPH-
oxidase or Nox) isoforms and inducible nitric oxide synthase (iNOS or Nos2) are major sources of elevated 
nitro-oxidative stress in the  heart6. In the CKD group, LV Nox4 expression showed a statistically non-significant 
Table 3.  qRT-PCR results at week 13. Values are presented as mean ± S.E.M., *p < 0.05 vs. sham-operated 
group, #p < 0.05 vs. CKD group (n = 6–10, One-Way ANOVA, Holm-Sidak post hoc test). Sham sham-operated 
group, CKD chronic kidney disease group, Adrb3 β-3 adrenergic receptor, Agt angiotensinogen, Agtr1a 
angiotensin-II receptor type 1a, Col1a1 collagen type 1 alpha 1 chain, Ctgf connective tissue growth factor, 
IL1 interleukin-1, IL6 interleukin-6, Myh6 α-myosin heavy chain, Myh7 β-myosin heavy chain, Nos2 inducible 
nitric oxide synthase, Nox4 NADPH-oxidase type 4, Nppa A-type natriuretic peptide, Nppb B-type natriuretic 




Sham CKD CKD + losartan CKD + mirabegron
Myh6/Ppia 1.41 ± 0.07 1.23 ± 0.11 1.21 ± 0.07 0.76 ± 0.09*#
Myh7/Ppia 1.29 ± 0.1 1.27 ± 0.18 0.71 ± 0.12*# 1.01 ± 0.14
Myh6/Myh7 0.94 ± 0.09 1.26 ± 0.15 0.61 ± 0.13# 1.32 ± 0.31
Col1a1/Ppia 0.2 ± 0.05 0.32 ± 0.08 0.25 ± 0.04 0.19 ± 0.06
Ctgf/Ppia 0.93 ± 0.09 1.32 ± 0.15* 0.82 ± 0.08# 1.91 ± 0.24*#
Nppa/Ppia 0.42 ± 0.09 0.63 ± 0.15 0.24 ± 0.02# 0.56 ± 0.05
Nppb/Ppia 1.05 ± 0.15 1.23 ± 0.11 0.64 ± 0.09# 1.19 ± 0.16
Nox4/Ppia 1.75 ± 0.18 2.38 ± 0.20 0.57 ± 0.09*# 1.25 ± 0.13*#
Nos2/Ppia 0.95 ± 0.19 2.80 ± 0.55* 1.26 ± 0.21# 1.17 ± 0.37#
IL1/Ppia 0.77 ± 0.05 1.18 ± 0.11* 0.78 ± 0.06# 0.94 ± 0.16
IL6/Ppia 0.81 ± 0.18 2.94 ± 0.6* 0.37 ± 0.08# 0.52 ± 0.12#
Tnf-α/Ppia 0.77 ± 0.05 1.2 ± 0.1* 0.83 ± 0.09# 0.99 ± 0.12
Agtr1a/Ppia 1.55 ± 0.06 1.13 ± 0.1* 1.26 ± 0.11 0.86 ± 0.08*#
Agt/Ppia 1.32 ± 0.09 1.24 ± 0.09 1.08 ± 0.12 1.12 ± 0.14
Adrb3/Ppia 0.65 ± 0.10 0.99 ± 0.07 0.9 ± 0.1 1.08 ± 0.21
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increase by 35% (p = 0.078), and Nos2 expression increased significantly compared to the sham-operated group 
(Table 3). Both losartan and mirabegron treatment significantly reduced the LV Nox4 and Nos2 expression com-
pared to the CKD or sham-operated groups (Table 3). The LV expressions of the inflammatory cytokines inter-
leukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-α (Tnf-α) were significantly increased in the 
CKD group as compared to the sham-operated group, indicating tissue inflammation (Table 3). Both losartan 
and mirabegron caused significant repression in the IL-6 mRNA levels compared to the CKD group (Table 3). 
Furthermore, losartan but not mirabegron decreased the expression of IL-1 and Tnf-α significantly as compared 
to the CKD group (Table 3). Angiotensin-II is known to increase the nitro-oxidative stress and inflammation 
via AT1 (Agtr1a) receptors by increasing NADPH-oxidase levels and inflammatory markers such as IL-6 and 
TNF-α28. Interestingly, LV Agtr1a was significantly repressed in the CKD group compared to the sham-operated 
group, probably as a compensatory mechanism of the chronically over-activated RAAS in CKD (Table 3). The 
losartan-treated CKD group showed no significant difference in the LV Agtr1a expression compared to the CKD 
or sham-operated groups. However, mirabegron-treatment significantly decreased the LV Agtr1a expression 
as compared to CKD or sham-operated groups (Table 3). There was no significant difference in the LV angio-
tensinogen (Agt) expression at the mRNA level between the groups (Table 3).
β3-AR expression did not increase in uremic cardiomyopathy irrespective of losartan or mira-
begron-treatment. Myocardial overexpression of the β3-AR was reported in heart failure of different 
 etiology14. LV β3-AR (Adrb3) mRNA expression showed only an increasing tendency in the CKD group com-
pared to the sham-operated group if analyzed by One-Way ANOVA in the four groups (Table 3). Notably, if only 
the sham-operated and the CKD groups were compared by unpaired t-test, the left ventricular β3-AR mRNA 
expression was significantly increased in the CKD group compared to the sham-operated group (0.99 ± 0.07 
vs. 0.65 ± 0.10 relative gene expression, p = 0.012). However, β3-AR protein levels failed to increase in the CKD 
group compared to the sham-operated group (Fig. 5a, Supplementary Fig. S1, and S2). Neither losartan nor mira-
begron changed the β3-AR mRNA or protein levels significantly in uremic cardiomyopathy (Table 3, Fig. 5a).
Figure 5.  The effects of losartan and mirabegron on the protein expression at week 13 assessed by Western 
blot. Left ventricular expression and cropped representative images of (a) beta-3 adrenergic receptor (β3-
AR), (b) endothelial nitric oxide synthase (eNOS), (c) phospho-eNOS, (d) phospho-eNOS/ eNOS ratio, (e) 
sarcoendoplasmic reticulum calcium ATPase 2a (SERCA2a), (f) phospholamban (PLN), (g) phospho-PLN 
(pPLN), and (h) phospho-PLN/PLN ratio. Values are presented as mean ± S.E.M., *p < 0.05 vs. sham-operated 
group, #p < 0.05 vs. CKD group (n = 6–7, One-Way ANOVA, Holm-Sidak post hoc test). Sham sham-operated 
group, CKD chronic kidney disease group, CKD + L losartan-treated chronic kidney disease group, CKD + M 
mirabegron-treated chronic kidney disease group. Images were captured with the Odyssey CLx machine and 
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Losartan but not mirabegron increased the eNOS protein level in uremic cardiomyopa-
thy. Decreased activity of endothelial NOS (eNOS) and nitric oxide (NO) bioavailability are considered 
major contributors to HFpEF and uremic  cardiomyopathy29,30. Accordingly, the LV expression of eNOS protein 
was significantly decreased in the CKD group compared to the sham-operated group in our model (Fig. 5b). 
Losartan treatment significantly increased the eNOS level; however, mirabegron treatment could not increase 
it (Fig. 5b, Supplementary Fig. S3, and S4). Phospho-eNOS protein level was significantly increased, but phos-
pho-eNOS/eNOS ratio did not increase significantly in the CKD group compared to the sham-operated group 
(Fig. 5c,d). Phospho-eNOS levels were not significantly different in losartan or mirabegron-treated CKD groups 
compared to the sham-operated group and were significantly decreased compared to the CKD group (Fig. 5c, 
Supplementary Fig. S5, and S6). There was no significant difference in the phospho-eNOS/eNOS ratio among 
the groups (Fig. 5d).
No changes in SERCA2a and phospholamban protein levels in uremic cardiomyopathy irre-
spective of losartan or mirabegron-treatment. Decreased SERCA2a expression and disturbed cal-
cium homeostasis are related to impaired diastolic relaxation and declining systolic  function31. In contrast, the 
SERCA2a protein level was not different in the experimental groups in our present study (Fig. 5e, Supplementary 
Fig. S7, and S8). The phosphorylation of phospholamban (PLN) can increase the SERCA activity and improve 
the speed of muscle  relaxation31. However, there was no difference in the PLN expressions between the groups 
(Fig. 5f, Supplementary Fig. S9, and S10). Notably, phospho-PLN (pPLN) protein levels showed a tendency of 
decrease in the CKD and mirabegron-treated CKD groups compared to the sham-operated group (p = 0.157 
and p = 0.137, respectively, unpaired t-test) (Fig. 5g, Supplementary Fig. S11, and S12). There was no significant 
difference in phospho-PLN protein level between the losartan-treated CKD and sham-operated or CKD groups 
(Fig. 5g). The phospho-PLN/PLN ratios did not decrease in the CKD group, and losartan or mirabegron did not 
change the phospho-PLN/PLN ratio in CKD (Fig. 5h).
Discussion
In the 5/6th nephrectomized rats, uremic cardiomyopathy developed with similar laboratory and cardiac altera-
tions to those in CKD-induced HFpEF patients. Our present study demonstrates first that there is no difference 
in the left ventricular β3-AR expression at the protein level in the HFpEF phase of uremic cardiomyopathy in 
rats. Here we also demonstrate for the first time in the literature that the β3-AR agonist mirabegron has no anti-
hypertrophic but mild anti-fibrotic and anti-inflammatory effects in uremic cardiomyopathy. These anti-fibrotic 
and anti-inflammatory effects seem to be independent of the β3-AR coupled eNOS-mediated pathways and 
might be explained by the effect of mirabegron causing repression on AT1 receptor in uremic cardiomyopathy. 
The ARB losartan significantly ameliorated the development of uremic cardiomyopathy via anti-hypertrophic, 
anti-fibrotic, anti-inflammatory, and eNOS-associated mechanisms.
Our present findings on the characteristic laboratory and echocardiographic parameters in CKD are consist-
ent with the literature data and our previous results in 5/6th nephrectomized  rats32–35. Our previous study showed 
no significant differences in the baseline laboratory and echocardiographic results between the sham-operated 
and CKD  animals35. Therefore, we did not characterize the baseline (i.e., pre-operative) laboratory and echo-
cardiographic parameters in our present study. In our present study, week 4 laboratory and echocardiographic 
parameters confirmed that 5/6th nephrectomized animals developed renal failure at the same severity in each 
CKD group before starting the drug administrations. We have found here characteristic laboratory changes in 
CKD, including increased serum urea and creatinine concentrations and urine protein levels and decreased 
creatinine clearance 13 weeks after the operations. Moreover, renal anemia, hypercalcemia, and hypercholester-
olemia developed in the 5/6th nephrectomized animals. In our CKD model, echocardiography confirmed the 
presence of uremic cardiomyopathy characterized by LVH and DD. Histology confirmed LVH at the cellular 
level and revealed LV fibrosis. According to these findings, the severity of CKD in our model corresponds to 
the human G2 or G3a CKD stages with mildly or moderately decreased kidney  function36,37. Notably, severe 
hypertension is usually not a feature of the 5/6th nephrectomy-induced CKD  models34. Indeed, our CKD model 
showed only a tendency of increase in blood pressure values. Therefore, DD might be developed due to LVH 
and fibrosis without severe hypertension.
Both pre-clinical and clinical studies showed that CKD-specific and non-specific risk factors such as uremic 
toxins, renal anemia, the over-activation of the RAAS and sympathetic nervous system, elevated nitro-oxidative 
stress, decreased NO levels, increased systemic and tissue inflammation could provoke the development of 
uremic  cardiomyopathy6,7. Indeed, our CKD model showed significantly elevated white blood cell count and 
overexpressed pro-inflammatory cytokines, including IL1, IL6, and Tnf-α in the left ventricle, indicating systemic 
and tissue inflammation. The interplay of increased nitro-oxidative stress and inflammation can be an essential 
contributor to LVH in  CKD3,6,7 and was linked to the progression of  HFpEF30. NOX, producing superoxide anion, 
may also be involved in the development of cardiac hypertrophy, interstitial fibrosis, or contractile  dysfunction38. 
Accordingly, LV Nox4 expression showed a statistically non-significant increase in our CKD model. Reduced NO 
bioavailability due to increased superoxide levels and consequential peroxynitrite formation might contribute to 
cardiomyocyte stiffness and fibrosis, leading to diastolic dysfunction and microvascular endothelial dysfunction 
in HFpEF and uremic  cardiomyopathy39. Our CKD model showed a decreased myocardial eNOS protein level, 
probably, due to the capillary rarefaction and hypertrophy in CKD, and a significantly elevated eNOS phos-
phorylation on the main activation site (Ser1177). The latter could be a compensatory mechanism to increase 
NO production in uremic cardiomyopathy. Accordingly, the p-eNOS/eNOS ratio was tendentiously increased 
in CKD as compared to the sham operated-group. Our results on eNOS expression and activity in uremic car-
diomyopathy are in line with the literature  data40. Furthermore, eNOS uncoupling leads to ROS/RNS instead 
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of NO production, increasing the nitro-oxidative stress and hypertrophic  remodeling39,41. According to studies 
using animal models and human myocardial samples, the up-regulation of iNOS (i.e., Nos2) can contribute to 
the dysregulation of NO production in oxidative and pro-inflammatory states leading to increased peroxyni-
trite production, which can be associated with pathologic cardiac  remodeling30,41. Indeed, in our present study, 
Nos2 expression was significantly increased in uremic cardiomyopathy. On the other hand, eNOS-derived NO 
production was demonstrated to enhance LV relaxation via PLN-mediated SERCA  Ca2+ re-uptake29. Decreased 
SERCA2a expression and disturbed calcium homeostasis could also be associated with impaired relaxation and 
declining systolic function in later stages of  HF31. In contrast, Silveira et al. found that SERCA2a and its regula-
tor PLN did not decrease in early isolated diastolic dysfunction induced by aortic  stenosis42. Primessnig et al. 
demonstrated in 5/6th-nephrectomy-induced CKD in rats that reduced phosphorylation of PLN could lead 
to reduced SERCA activity 8 weeks after the operation. However, they found increased PLN phosphorylation 
24 weeks after the operation, pointing out the time-dependency of PLN phosphorylation and SERCA activity 
in uremic  cardiomyopathy43. In our study, there was no significant change in SERCA2a and PLN expressions 
13 weeks after the operations in CKD. These results might be explained by the longer follow-up time in our study 
than the 8-week follow-up period used in the study of Primessnig et al.43. Losartan and mirabegron did not 
change the SERCA expression and pPLN/PLN expressions in CKD, suggesting that these proteins did not play 
a crucial role in the effects causing improved diastolic function in the losartan and mirabegron-treated groups.
Most of the standard therapies in uremic cardiomyopathy are supportive and used to modulate comor-
bidities or heart failure slowing down the progression of the  condition44. RAAS inhibitors, including ARBs, 
are cornerstone therapies to reduce proteinuria, CKD progression, and cardiovascular  risk45. The ARB losartan 
was reported to ameliorate LVH and myocardial fibrosis development and improve cardiac function in 5/6th 
nephrectomized rats and end-stage renal disease  patients46,47. In our present study, losartan failed to improve the 
main routine laboratory parameters of kidney function, including creatinine clearance, serum carbamide, and 
creatinine levels. However, it reduced the urine volume and the remnant kidney weight compared to the CKD 
group showing a mild renoprotective effect. The further histological or molecular examination of the kidneys 
was out of the scope of the present study.
Evidence suggests that chronic over-activation of the RAAS and the sympathetic nervous system in HF also 
stimulates the inflammatory processes and increases nitro-oxidative stress, further aggravating each  other48,49. 
Angiotensin-II has been reported to activate cardiac NADPH-oxidase via AT1 receptor and, subsequently, the 
over-production of ROS/RNS. The increased nitro-oxidative stress could trigger the production of pro-inflam-
matory mediators, such as IL1, IL6, TNF-α, and tissue growth factor-beta (TGF-β)49,50, and the inflammatory 
cytokines could decrease eNOS expression and NO bioavailability, contributing to cardiac remodeling and  HF28. 
Therefore, AT1 blockade by losartan is a rational therapeutic option to ameliorate cardiac remodeling by reduc-
ing nitro-oxidative stress, inflammatory processes and improve NO bioavailability in uremic cardiomyopathy. 
Indeed, in our present study, losartan improved the DD, LVH, and cardiac fibrosis, probably via blocking the AT1 
receptor-mediated nitro-oxidative (Nox4 and Nos2) and inflammatory (IL1, IL6, and Tnf-α), and eNOS-associated 
mechanisms in our CKD model. Interestingly, it has been reported that another ARB, valsartan combined with 
the neprilysin inhibitor sacubitril (LCZ696) attenuated cardiac hypertrophy and fibrosis in 5/6th nephrectomized 
 rats51 and in human phase I clinical trials in advanced CKD patients with HF (clinical trial No.: NCT03771729 
and NCT04218435). Taken together, our present results are in line with the literature data on the antiremodeling 
effects of ARBs in uremic cardiomyopathy.
Modulation of NO signaling is considered one of the novel promising approaches in HFpEF  treatment41. 
β3-AR agonists are reported to ameliorate cardiac remodeling, diastolic and systolic dysfunction via the β3-AR 
receptor coupled eNOS-derived NO production beyond other mechanisms such as preserving the function 
of the  Na+/K+-ATP-ase, antioxidant effects via the AKT-NO-mPTP signaling, and influencing the fatty acid 
 metabolism14,39,41,52. Currently, phase II and III clinical trials are investigating the antiremodeling effects of 
the β3-AR agonist mirabegron on the development of LVH and HFpEF (NYHA I-II stages, clinical trial No.: 
NCT02599480), and HFrEF (NYHA III-IV stages, clinical trial No.: NCT01876433 and NCT03926754). Notably, 
kidney function is often decreased in HFpEF and HFrEF patients, and chronic heart failure aggravates renal 
dysfunction mutually. This bidirectional interaction of renal and heart failure is the key concept in cardio-renal 
 syndrome53,54. Dysfunction of each organ can induce and perpetuate injury in the other via complex hemody-
namic, neurohormonal, and biochemical pathways such as over-activated RAAS and sympathetic nervous system, 
increased nitro-oxidative stress, and inflammatory  pathways6. Notably, patients with uncontrolled hypertension, 
severe anemia, moderately or severely decreased renal function (eGFR < 30 or 50 mL/min corresponding to 
G3b-G5 CKD stages, respectively) were excluded from the aforementioned phase II and phase III clinical trials. 
Thus, to our best knowledge, the antiremodeling effects of mirabegron were not investigated in a selected patient 
population suffering from uremic cardiomyopathy. Considering the exclusion criteria of the aforementioned 
clinical trials, we aimed to investigate the effects of mirabegron in mild to moderate experimental uremic car-
diomyopathy. In our study, mirabegron did not affect the major parameters of renal function, including serum 
carbamide and creatinine levels, creatinine clearance, and urine volume at the endpoint. However, it had several 
adverse effects on glomerular function, worsening the proteinuria, renal anemia, serum total cholesterol, and 
LDL-cholesterol levels in our CKD model. Although mirabegron repressed the left ventricular IL6 level, white 
blood cell count remained elevated, suggesting the presence of low-grade systemic inflammation in CKD irre-
spective of mirabegron-treatment.
In our present study, mirabegron could not prevent the development of left ventricular hypertrophy assessed 
by M-mode echocardiography and histology in CKD. We speculate that the failing β3-AR overexpression and the 
β3-AR-coupled activation of eNOS-mediated pathways are responsible for its missing anti-hypertrophic effects in 
CKD. Notably, if only the sham-operated and CKD groups were compared by unpaired t-test, the left ventricular 
β3-AR mRNA expression was significantly increased in the CKD group compared to the sham-operated group 
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(p = 0.012, Table 3). However, the protein level showed no difference between the groups (p = 0.336, Fig. 5a). This 
could be explained by (i) increased degradation and turnover rate of proteins in CKD as it is considered as a cata-
bolic  state55, and (ii) the β3-AR expression could be regulated time-dependently in uremic cardiomyopathy. We 
also measured the left ventricular β3-AR mRNA and protein levels at an earlier follow-up time point in the same 
CKD model 5/6 nephrectomy-induced CKD in male Wistar rats 9 weeks after the operations (Supplementary 
Fig. S13). At this time, HFpEF is also developed, as we described  previously35. At this earlier follow-up time point, 
the left ventricular expression of β3-AR mRNA was also significantly increased in the CKD group as compared 
to the sham-operated group, and there was no significant change in the β3-AR protein level between the groups, 
similarly to the week 13 findings (Supplementary Fig. S13). However, it could not be excluded that the β3-AR 
protein expression might change in a later phase of uremic cardiomyopathy. Notably, Miao et al. demonstrated in 
aortic banding-induced heart failure in rats that the cardiac expression of β3-AR mRNA and protein expressions 
in myocardial tissues showed a positive correlation with aging and the severity of heart  failure56.
Most studies investigating the effects of β3-AR agonists in heart failure demonstrated that β3-AR agonists 
attenuated cardiac hypertrophy and fibrosis and improved cardiac contractility via coupling of β3-AR to the 
eNOS/cGMP pathway as the main  mechanism14,52. Therefore, we also investigated the left ventricular expression 
of eNOS, p-eNOS, and their ratio in our study. Mirabegron did not increase the total eNOS level and significantly 
decreased the p-eNOS level as compared to the CKD group. Therefore, it seems that the β3-AR is uncoupled 
from eNOS or unable to activate it, probably, due to elevated nitro-oxidative stress, inflammatory mechanisms, 
and uremic toxins-induced  alterations40. The precise mechanistic characterization of CKD-induced changes of 
the β3-AR-mediated pathways was out of the scope of the present study.
However, in our present study, mirabegron had beneficial effects on DD characterized by e’ and E/e’, and 
cardiac fibrosis assessed by histology and left ventricular expressions of Col1a1 and Ctgf. We hypothesized that 
mirabegron could have its antiremodeling effects independently of the β3-AR-eNOS-mediated pathway in uremic 
cardiomyopathy. Interestingly, mirabegron reduced the left ventricular expression of the AT1 receptor in uremic 
cardiomyopathy. This finding is particularly interesting since the chronic administration of the β3-AR agonists 
BRL37344 could down-regulate the AT1 receptor expression and up-regulate the AT2 receptor expression in the 
 pancreatic23 and lung  tissues24 of male apoE knock-out mice. Interestingly, Belge et al. demonstrated that angi-
otensin-II administration did not induce cardiac fibrosis and hypertrophy in mice with cardiomyocyte-specific 
expression of human β3-AR22. Recently, Kamiya et al. demonstrated that chronic infusion of a β3-adrenergic 
receptor agonist attenuated cardiac fibrosis and improved diastolic dysfunction independently of blood pressure 
in an angiotensin-II-induced heart failure model with hypertension in  mice57. These results suggest that chronic 
β3-adrenoceptor activation regulates the expression of angiotensin-II receptor types, and these interactions may 
play a protective role in lung, pancreatic, and other tissues such as the heart. The chronic over-activation of the 
AT1 receptor could play a major role in oxidative stress, inflammation, and ultimately fibrosis in the development 
of heart  failure58,59. Indeed, in our present study, mirabegron significantly reduced the left ventricular expression 
of the nitro-oxidative stress markers Nox4 and Nos2 and the inflammatory marker IL6 in uremic cardiomyopathy. 
Our present results are in line with these literature data since mirabegron treatment significantly reduced the AT1 
receptor expression in uremic cardiomyopathy, which might lead to its antioxidant, anti-inflammatory, and anti-
fibrotic effects independently of the eNOS/cGMP-mediated pathway in uremic cardiomyopathy. Moreover, Hadi 
et al. demonstrated the dual antioxidant role of β3-ARs in macrophages: (i) β3-AR decreases ROS production by 
directly inhibiting NADPH-oxidase activity; and (ii) β3-AR induces the expression of catalase, a major hydrogen 
peroxide  scavenger58. They also confirmed that β3-AR stimulation inhibited the ROS-dependent nuclear fac-
tor kappa-light-chain-enhancer of activated B cell (NF-κB) inflammatory pathway in the  uterus58. In another 
study, β3-AR stimulation inhibited cytokine production, including TNF-α and IL6, to prevent myometrial cell 
apoptosis and extracellular matrix  remodeling59. However, these secondary antioxidant and anti-inflammatory 
mechanisms of the β3-AR induction by mirabegron are not well-characterized in HF. Our present finding on the 
antiremodeling effects of mirabegron independently of β3-AR-eNOS mediated pathways could be interesting for 
physicians treating heart failure patients with reduced renal function since mirabegron could have anti-fibrotic 
effects in the early stages of uremic cardiomyopathy. Therefore, the involvement of early-stage CKD patients in 
clinical studies investigating the effects of mirabegron could be considered in the future.
In summary, our present study suggests that the development of uremic cardiomyopathy might be prevented 
or markedly slowed down by losartan if its administration starts in early CKD stages without manifest LVH. In 
contrast, mirabegron failed to improve the severity of LVH, but had several beneficial effects on diastolic dys-
function, fibrosis, and tissue inflammation in uremic cardiomyopathy. These antiremodeling effects seem to be 
independent of the β3-AR/eNOS mediated pathways in uremic cardiomyopathy and probably associated with the 
effects of mirabegron downregulating the AT1 receptor. Mirabegron had adverse effects on glomerular function 
with worsening anemia, proteinuria, and serum cholesterol levels in our CKD model. Therefore, the elevated 
mortality risk and the possibility of future cardiovascular events might remain high in CKD patients treated by 
mirabegron. In future studies, the combination of mirabegron with ARBs or cholesterol-lowering drugs such as 
statins might be rational to potentiate the antiremodeling effects and prevent the adverse effects of mirabegron.
Limitations
The purpose of this study was to evaluate and compare the effects of chronic administration of ARB losartan 
and β3-AR agonist mirabegron on cardiac remodeling, function, and the development of HFpEF in uremic car-
diomyopathy in rats. Uremic cardiomyopathy is a unique entity most commonly manifested as left ventricular 
hypertrophy with preserved ejection fraction and predisposing the heart for further cardiovascular complica-
tions in  CKD60. However, there are still many unknown mechanisms, such as the exact role of β3-AR in the 
development of uremic cardiomyopathy. We demonstrated here that there is no difference in the left ventricular 
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β3-AR expression at the protein level 13 weeks after the 5/6th nephrectomy in rats. However, it could not be 
excluded that the β3-AR protein expression might change in a later HFrEF phase of uremic cardiomyopathy. The 
time-dependent and mechanistic investigation of the cardiac β3-AR expression in the development of uremic 
cardiomyopathy was out of the scope of the present study. Notably, the precise mechanisms and functional role 
of the β3-AR in heart failure induced by different cardiovascular diseases, including diabetes mellitus, acute 
myocardial infarction, or chemotherapy-induced heart failure forms, are also not fully discovered. Therefore, 
we focused mainly on the potential protective effects of mirabegron in CKD, investigating the well-known 
markers of uremic cardiomyopathy and the effects caused by mirabegron. The deep mechanistic insight of the 
antiremodeling effects of mirabegron was out of the scope of our present descriptive study. We found here mod-
erate antiremodeling effects of mirabegron and hypothesized that mirabegron could have anti-fibrotic effects in 
uremic cardiomyopathy independently of the β3-AR-eNOS-mediated pathway, but probably associated with its 
effects causing repression on the AT1 receptor. However, further mechanistic studies are needed to explore the 
antiremodeling effects of mirabegron in uremic cardiomyopathy.
Materials and methods
This investigation conformed to the National Institutes of Health Guide for the Care and Use of Laboratory Ani-
mals (NIH Publication No. 85–23, Revised 1996) and was approved by the Animal Research Ethics Committee of 
Csongrád County (XV./799/2019) and the University of Szeged in Hungary. All institutional and national guide-
lines for the care and use of laboratory animals were followed. The authors complied with the ARRIVE guidelines.
Animals. In this study, a total of 45 adult male Wistar rats (Rattus norvegicus, 8 weeks old, 280–340 g) were 
housed in pairs in individually ventilated cages (Sealsafe IVC system, Tecniplast S.p.A., Italy). The rats were 
maintained with 12 h:12 h light/dark cycles in a temperature-controlled room throughout the study. Standard 
rat chow and tap water were supplied ad libitum.
Experimental setup. Control animals underwent sham-operation (n = 10), and experimental CKD (n = 35) 
was induced by 5/6th nephrectomy in two phases. After the operations, rats were followed-up for 13  weeks 
(Fig. 1). On the first day of the 5th follow-up week, rats were divided into the following four groups and treated 
via oral gavage daily for 8 weeks: (1) sham-operated group treated with per os tap water (n = 10, 2 mL/kg/day), 
(2) CKD group treated with per os tap water (n = 13, 2 mL/kg/day), (3) CKD group treated with per os losartan 
(n = 12, 10 mg/kg/day dissolved in tap water in 2 mL/kg end volume, Arbartan 50 mg film-coated tablets, Teva 
Pharmaceutical Industries Ltd., Hungary), and (4) CKD group treated with per os Mirabegron (n = 10, 10 mg/
kg/day in tap water 2 mL/kg end volume; Betmiga 50 mg prolonged-release tablets, Astellas Pharma Europe B.V., 
Netherland) (Fig. 1). In our study, 6 animals died from the nephrectomized groups (2 animals in the CKD group, 
1 animal in the losartan-treated CKD group, and 3 animals in the mirabegron-treated CKD group). At weeks 
4 and 12, cardiac morphology and function were assessed by transthoracic echocardiography (Fig. 1). Blood 
was collected from the saphenous vein at week 4 and from the abdominal aorta at week 13 to measure serum 
parameters. The animals were placed into metabolic cages (Tecniplast S.p.A., Italy) for 24 h at weeks 4 and 12 
to measure urine creatinine and protein levels (Fig. 1). At week 13, invasive blood pressure measurements were 
performed in a subgroup of animals (Fig. 1) (n = 6–8). At week 13, hearts were isolated, then left ventricular sam-
ples were prepared for histology and biochemical measurements. The development of LVH and fibrosis in CKD 
was verified by the measurement of cardiomyocyte diameters and cross-sectional areas on hematoxylin–eosin 
(HE) stained slides and picrosirius red/fast green-stained (PSFG) slides. Total RNA was isolated from the left 
ventricles, and the myocardial expression of Adrb3, Agt, Agtr1a, Col1a1, Ctgf, IL1, IL6, Myh6, Myh7, Nos2, Nox4, 
Nppa, Nppb, and Ppia were measured by qRT-PCR. Moreover, LV expression of β3-AR, total-eNOS, phospho-
eNOS, PLN, phospho-PLN, and SERCA2a were measured by Western blot.
5/6th nephrectomy. Sham operation and 5/6th nephrectomy were performed in two phases as described 
 previously33,35 (Fig.  1). Briefly, anesthesia was induced by intraperitoneal injection of pentobarbital sodium 
(Euthasol, Produlab Pharma B.V., Netherlands; 40 mg/kg). At the first operation, the 1/3 left kidney on both 
ends was excised. One week after the first operation, animals were anesthetized again, and the right kidney was 
removed. During sham operations, only the renal capsules were removed. After the surgeries, the incision was 
closed with running sutures, and povidone-iodine was applied on the surface of the skin. As a postoperative 
medication, sc. 0.3 mg/kg nalbuphine hydrochloride (Nalbuphine 10 mg/ml, Teva Pharmaceutical Industries 
Ltd., Hungary) was administered for 4 days, twice in the first two postoperative days and once in the third and 
fourth post-operative days. Enrofloxacin antibiotics (Enroxil 75  mg tablets, Krka, Slovenia; dissolved in tap 
water in 3.5 mg/L end concentration) were administered in the drinking water for 4 days after both surgeries.
Transthoracic echocardiography. Cardiac morphology and function were assessed by transthoracic 
echocardiography at weeks 4 and 12 as we described  previously35,61–63 (Fig. 1). Rats were anesthetized with 2% 
isoflurane (Forane, Aesica, Queenborough Limited, UK). Two-dimensional, M-mode, Doppler, tissue Doppler, 
and 4 chamber-view images were performed by the criteria of the American Society of Echocardiography with 
a Vivid IQ ultrasound system (General Electric Medical Systems, USA) using a phased array 5.0–11 MHz trans-
ducer (GE 12S-RS probe). Data of three consecutive heart cycles were analyzed (EchoPac Dimension v201, 
General Electric Medical Systems, USA; https:// www. gehea lthca re. com/ produ cts/ ultra sound/ vivid/ echop ac) by 
an experienced investigator in a blinded manner. The mean values of three measurements were calculated and 
used for statistical evaluation.
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Blood pressure measurement. To measure arterial blood pressure in a separated subgroup of animals, 
a PE50 polyethylene catheter (Cole-Parmer, USA) was inserted into the left femoral artery at week 13 under 
pentobarbital anesthesia (Euthasol, Produlab Pharma B.V., Netherlands; 40 mg/kg) as described  previously35,64. 
Blood pressure measurements were performed between 09:00 and 14:00 h.
Serum and urine laboratory parameters. Serum carbamide and creatinine levels were quantified by 
kinetic UV method using urease and glutamate dehydrogenase enzymes and Jaffe method, respectively. Serum 
sodium, potassium, and chloride levels were determined by indirect potentiometry using ion-selective elec-
trodes. The serum calcium, magnesium, phosphate levels were quantified by complex formation methods. All 
reagents and instruments for the serum parameter measurements were from Roche Diagnostics (Hoffmann-La 
Roche Ltd, Switzerland), as described  previously33,35. Urine creatinine and urine protein levels were measured by 
standard laboratory methods as described  previously33,35. At week 13, serum total cholesterol, HDL-cholesterol 
and triglyceride levels were measured by Roche Cobas 8000 analyzer system using enzymatic colorimetric assays 
from Roche (Hoffmann-La Roche Ltd, Switzerland)65,66. LDL-cholesterol was calculated according to the Friede-
wald formula. Total blood count and hematocrit were measured from whole blood by a hematology analyzer 
(XE-2100, Sysmex Corporation, Japan) at week 13 to verify the development of chronic systemic inflammation 
and renal anemia.
Tissue harvesting. At week 13, hearts were isolated under pentobarbital anesthesia, and the blood was 
washed out in calcium-free Krebs–Henseleit solution. Then the hearts were weighed, left and right ventricles 
were separated and weighed, and the cross-section of the left ventricle at the ring of the papillae was cut and fixed 
in 4% buffered formalin for histological analysis. Other parts of the left ventricles were freshly frozen in liquid 
nitrogen and stored at − 80 °C until further biochemical measurements. Body weight, tibia length, left kidney 
weight, and weight of lungs were measured at week 13.
Hematoxylin–eosin and picrosirius red and fast green stainings. 5 μm paraffin-embedded trans-
verse cut sections of the formalin-fixed subvalvular areas of the left ventricles were stained with hematoxy-
lin–eosin (HE) or picrosirius red and fast green (PSFG) as described  previously35,62,63. Histological slides were 
scanned with a Pannoramic Midi II scanner (3D-Histech, Hungary). On the digital HE images, cardiomyocyte 
diameters and cross-sectional areas were measured to verify the development of LVH at the cellular level. For 
the evaluation, the Biology Image Analysis Software (BIAS) was  used67. BIAS (internal built, dated December 
2019; https:// single- cell- techn ologi es. com/ bias/) is developed by Single-Cell Technologies Ltd., Hungary and the 
first publicly available version expected to be released in late 2021. Image pre-processing was followed by deep 
learning-based cytoplasm segmentation. User-selected objects were forwarded to the feature extraction module, 
configurable to extract properties from the selected cell components. Here, transverse transnuclear cardiomyo-
cyte diameter was measured in 100 selected, longitudinally oriented, mono-nucleated cardiomyocytes on left 
ventricular sections cut on the same plane. Cardiomyocyte cross-sectional areas of the same cells were calculated 
by the software as well. Cardiac fibrosis was assessed on PSFG slides with an in-house developed  program35,62,63. 
Representative HE- and PSFG-stained slides were captured in Panoramic Viewer 1.15.4 (3D-Histech, Hungary; 
https:// old. 3dhis tech. com/ panno ramic_ viewer).
mRNA expression profiling by qRT-PCR. Quantitative RT-PCR was performed with gene-specific prim-
ers to monitor mRNA expression. RNA was isolated using QIAGEN RNeasy Fibrous Tissue Mini Kit (QIAGEN, 
Germany) from heart tissue. Then 100 μg of total RNA was reverse transcribed using iScript cDNA Synthesis 
Kit (Bio-Rad Laboratories Inc., USA). Specific primers (Adrb3: β-3 adrenergic receptor, #qRnoCED0006313; 
Agt: angiotensinogene, #qRnoCED0051666; Agtr1a: angiotensin-II receptor type 1, #qRnoCID0052626; Col1a1: 
collagen type 1 alpha 1 chain, #qRnoCED0007857; Ctgf: connective tissue growth factor, #qRnoCED0001593; 
IL1: interleukin-1, #qRnoCID0002056; IL6: interleukin-6, #qRnoCID0053166; Myh6: α-myosin heavy chain, 
#qRnoCID0001766; Myh7: β-myosin heavy chain, #qRnoCED0001215; Nos2: inducible nitric oxide synthase, 
#qRnoCID0017722; Nox4: NADPH-oxidase type 4, #qRnoCID0003969; Nppa: A-type natriuretic peptide, 
#qRnoCED0006216; Nppb: B-type natriuretic peptide, #qRnoCED0001541; Ppia: peptidyl-prolyl isomerase A, 
#qRnoCID0056995; Tnf-α: tumor necrosis factor-α, #qRnoCED0009117) and SsoAdvanced Universal SYBR 
Green Supermix (BioRad Laboratories Inc., USA) were used according to the manufacturer’s instructions. Ppia 
was used as a house keeping control gene for normalization.
Western blot. Standard Western blot technique was used in the case of β3-AR with actin, eNOS, phos-
pho-eNOS, SERCA2a with α-tubulin, and PLN, phospho-PLN with GAPDH loading background as described 
 previously68 (Supplementary Fig. S1-13). Left ventricular samples (n = 28) were homogenized with an ultrasoni-
cator (UP100H, Hielscher Ultrasonics GmbH, Germany) in Radio-Immunoprecipitation Assay (RIPA) buffer 
(50  mM Tris–HCl (pH 8.0), 150  mM NaCl, 0.5% sodium deoxycholate, 5  mM ethylenediamine tetra-acetic 
acid (EDTA), 0.1% sodium dodecyl sulfate, 1% NP-40; Cell Signaling Technology Inc., USA) supplemented 
with phenylmethanesulfonyl fluoride (PMSF; Sigma-Aldrich, USA), sodium orthovanadate  (Na3VO4; Sigma-
Aldrich, USA) and sodium fluoride (NaF; Sigma-Aldrich, USA). The crude homogenates were centrifuged at 
15,000 × g for 30 min at 4 °C. After quantifying the supernatants’ protein concentrations using the BCA Protein 
Assay Kit (Pierce Thermo Fisher Scientific Inc., USA), 25 μg of reduced and denaturized protein was loaded. 
Then sodium dodecyl-sulphate polyacrylamide gel electrophoresis (SDS-PAGE, 50 V, 4 h) was performed (6% 
gel in case of eNOS, phospho-eNOS and SERCA2a, 10% gel in case of β3-AR, and 12% gel in case of PLN, 
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phospho-PLN,) followed by the transfer of proteins onto a nitrocellulose membrane (10% methanol in case of 
eNOS, phospho-eNOS and SERCA2a and 20% methanol in case of β3-AR, PLN and phospho-PLN, 35 V, 2 h). 
The efficacy of transfer was checked using Ponceau staining. The membranes were cut vertically and horizontally 
into parts corresponding to the molecular weights of β3-AR, eNOS, phospho-eNOS, SERCA, PLN, phospho-
PLN, GAPDH, actin, and α-tubulin. Membranes were blocked for 1 h in 5% (w/v) bovine serum albumin (BSA, 
Sigma-Aldrich, USA) supplemented with  Na3VO4 and NaF, and were incubated with primary antibodies in 
the concentrations of 1:1000 against eNOS (#32027S, Cell Signaling Technology Inc.,  USA69), PLN (#14562S, 
Cell Signaling Technology Inc.,  USA70), phospho-PLN (Ser16/Thr17, #8496S, Cell Signaling Technology Inc., 
 USA71), SERCA2a (#4388S, Cell Signaling Technology Inc.,  USA72), actin (612,656, BD Bioscienses,  USA73) 
and α-tubulin (#2144S, Cell Signaling Technology Inc.,  USA74) or 1:5000 against GAPDH (#2118, Cell Signal-
ing Technology Inc.,  USA75) or 1:500 against phospho-eNOS (Ser1177, #9570S, Cell Signaling Technology Inc., 
 USA76) and β3-AR (AB101095, Abcam PLC,  UK77) overnight at 4 °C in 5% BSA. Then the membranes were 
incubated with IRDye 800CW Goat Anti-Rabbit and/or IRDye 680RD Goat Anti-Mouse secondary antibody 
(LI-COR Biosciences, USA, in the concentrations of 1:5000) for 1 h at room temperature in 5% BSA to detect 
proteins with similar molecular weight on the same membrane where it is applicable. Fluorescent signals were 
detected by Odyssey CLx machine (LI-COR Biosciences, USA), and digital images were captured with Image 
Studio 5.2.5 (LI-COR Biosciences, USA; https:// www. licor. com/ bio/ image- studio/). Then images were analyzed 
and evaluated by Quantity One 4.4.0 (Bio-Rad Laboratories Inc., USA; https:// www. bio- rad. com/ en- hu/ produ 
ct/ quant ity- one-1- d- analy sis- softw are? ID= 1de9e b3a- 1eb5- 4edb- 82d2- 68b91 bf360 fb).
Statistical analysis. Statistical analysis was performed using GraphPad Prism 6.01 for Windows (Graph-
Pad Software Inc., USA; https:// www. graph pad. com/ scien tific- softw are/ prism/). All values are presented as 
mean ± S.E.M., p < 0.05 was accepted as a statistically significant difference. One-Way ANOVA was used to deter-
mine the statistical significance between all measured parameters within each time point. Two-way repeated-
measures ANOVA was used to determine the effects of CKD and the treatments on serum, urine, and echocar-
diographic parameters between week 4 and endpoint follow-up data. Holm-Sidak test was used as a post hoc 
test. In cases of phospho-eNOS/eNOS, SERCA2a, and phospho-PLN Western blot results, unpaired t-test was 
also used to investigate the statistical significance between CKD vs. sham-operated groups or drug-treated CKD 
vs. CKD groups (p-values are mentioned in the text).
Data availability
The data generated and analyzed during the current study are available from the corresponding authors on a 
reasonable request.
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